Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from toto

 

Commission File Number: 001-40386

A logo with blue and black letters

Description automatically generated

ONEMEDNET CORPORATION

(Exact name of registrant as specified in its charter)

Data Knights Acquisition Corp.Delaware

35-2303727

(Exact name of registrant as specified in its charter)

Delaware

86-2076743

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

No.)

Unit G6, Frome Business Park, Manor Road

Frome6385 Old Shady Oak Rd., Suite 250
Eden Prairie, MN

55344

United Kingdom

BA11 4FN

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code:011-44 203 833 4000

(Former name or former address, if changed since last report)

800-918-7189

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classEach Class

Trading Symbol(s)

Name of each exchangeEach Exchange on which registeredWhich Registered

Units, each consisting of one share of Class A Common Stock, and one Redeemable Warrantpar value $0.0001 per share

DKDCUONMD

The Nasdaq Stock Market, LLC

Class A Common Stock, $0.0001 par value per share

DKDCA

The Nasdaq Stock Market LLC

Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share

DKDCWONMDW

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive DateData File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large acceleratedlarge-accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated“large-accelerated filer,” “accelerated filer,” “non-accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large-accelerated filer ☐

Accelerated filer ☐

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 14,November 20, 2023, there were 3,316,81932,263,342 shares of the Company’s Class A Common Stock, $0.0001 par value $0.0001 per share, (the “Class A Common Stock”), and 4,253,517 of the Company’s Class B Common Stock, $0.0001 par value per shareregistrant issued and outstanding (the “Class B Common Stock”).

outstanding.

ONEMEDNET CORPORATION

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2023

Table of Contents

DATA KNIGHTS ACQUISITION CORP.

TABLE OF CONTENTS

Page

PART I  – FINANCIAL INFORMATION:

PART I. FINANCIAL INFORMATION

Item 1.1

Financial Statements:Statements

F-1

Condensed Consolidated Balance SheetSheets as of JuneSeptember 30, 2023 (Unaudited) and as of December 31, 2022(Audited)2022 (Unaudited)

1

F-1

Condensed Consolidated Statements of Operations for the threeThree and six months ended JuneNine Months Ended September 30, 2023 (Unaudited) and for the three and six months ended June 30, 2022 (Unaudited)

2

F-2

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and six monthsNine Months ended JuneSeptember 30, 2023 (Unaudited) and for the three and six months ended JuneSeptember 30, 2022 (Unaudited)

3

F-3

Condensed Consolidated StatementStatements of Cash Flows for the six months ended JuneNine Months Ended September 30, 2023 (Unaudited) and for the six months ended JuneSeptember 30, 2022 (Unaudited)

4

F-4

Notes to Condensed Consolidated Financial Statements (Unaudited)

5

F-5

Item 2.2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

4

Item 3.3

Quantitative and Qualitative Disclosures About Market Risk

30

12

Item 4.4

Controls and Procedures

30

12

PART II -II. OTHER INFORMATION:INFORMATION

32

Item 1.1

Legal Proceedings

32

13

Item 1A.1A

Risk Factors

32

13

Item 2.2

Unregistered Sales of Equity Securities and Use of Proceeds

32

13

Item 3.3

Defaults Upon Senior Securities

32

13

Item 4.4

Mine Safety Disclosures

32

13

Item 5.5

Other Information

32

13

Item 6.6

Exhibits

33

13
SIGNATURES14

2


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and the documents incorporated herein by reference contain forward-looking statements. Such forward-looking statements are based on current expectations, estimates and projections about OneMedNet Corporation’s industry, management beliefs, and assumptions made by management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict; therefore, actual results and outcomes may differ materially from what is expressed or forecasted in any such forward-looking statements. Although we believe the expectations reflected in our forward-looking statements are based upon reasonable assumptions, it is not possible to foresee or identify all factors that could have a material effect on the future financial performance of the Company. The forward-looking statements in this Quarterly Report on Form 10-Q are made on the basis of management’s assumptions and analyses, as of the time the statements are made, in light of their experience and perception of historical conditions, expected future developments and other factors believed to be appropriate under the circumstances. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q and the information incorporated by reference in this Quarterly Report on Form 10-Q to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

3

i

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Financial Statements:

Condensed Consolidated Balance Sheet as of June 30, 2023 (Unaudited) and as of December 31, 2022 (Audited)

1

Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 (Unaudited) and for the three and six months ended June 30, 2022 (Unaudited)

2

Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2023 (Unaudited) and for the three and six months ended June 30, 2022 (Unaudited)

3

Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2023 (Unaudited) and for the six months ended June 30, 2022 (Unaudited)

4

Notes to Condensed Consolidated Financial Statements (Unaudited)

5

ONEMEDNET CORPORATION

ii

Table of Contents

DATA KNIGHTS ACQUISITION CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

    

June 30, 

    

December 31, 

    

2023

2022

(Unaudited)

(Audited)

ASSETS

Current assets

Cash

$

3,438

$

30,870

Total Current Assets

3,438

30,870

 

 

Investments held in Trust Account

29,978,639

29,029,416

Total assets

$

29,982,077

$

29,060,286

LIABILITIES AND STOCKHOLDER’S EQUITY

 

  

 

  

Current Liabilities

Accrued expenses

$

2,039,294

$

1,679,821

Amount due to related parties

11,200

11,500

Income tax payable

32,304

214,850

Franchise tax payable

8,000

69,966

Total Current Liabilities

2,090,798

1,976,137

Warrant liabilities

 

362,558

362,558

Deferred underwriter fee payable

4,025,000

4,025,000

Extension loan

3,283,358

207,081

Working capital loans

367,832

2,545,838

Total liabilities

 

10,129,546

9,116,614

Commitments and Contingencies

 

  

 

  

Class A Common Stock subject to possible redemption; 2,731,544 shares at redemption value of $10.96 and $10.53 per share as of June 30, 2023 and December 31, 2022, respectively

29,938,336

28,750,110

 

 

Stockholders’ Deficit

 

 

Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding

 

 

Class A Common Stock, $0.0001 par value; 100,000,000 shares authorized; 585,275 issued and outstanding, excluding 2,731,544 shares subject to redemption as of June 30, 2023 and December 31, 2022, respectively

 

59

59

Class B Common Stock, par value $0.0001; 10,000,000 shares authorized; 4,253,517 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

425

425

Additional paid-in capital

 

1,637,597

2,242,253

Accumulated deficit

 

(11,723,886)

(11,632,745)

Total Stockholders’ Deficit

 

(10,085,805)

(8,806,438)

Total Liabilities and Stockholders’ Deficit

$

29,982,077

$

29,060,286

(UNAUDITED)

       
  September 30,
2023
  December 31,
2022
 
ASSETS        
Current Assets        
Cash and cash equivalents $611,822  $270,859 
Accounts receivable, net of allowance  86,392   18,975 
(2023 $0 and 2022 $102,700)        
Accounts receivable, net of allowance (2023 $0 and 2022 $102,700)  86,392   18,975 
Prepaid expenses and other assets  87,387   100,945 
Receivable from SPAC IPO Costs  2,059,975   900,152 
         
Total current assets  2,845,576   1,290,931 
         
Property and Equipment, Net  92,368   83,097 
         
Total assets $2,937,944  $1,374,028 
         
Liabilities and Stockholders’ Equity (Deficit)        
Current Liabilities        
Accounts payable & accrued expenses  1,475,276  $1,134,752 
Deferred revenues  393,780   183,683 
Convertible promissory notes  12,365,000   8,490,000 
Canada Emergency Business Loan Act  44,330   - 
Total current liabilities  14,278,386   9,808,435 
         
Long Term Liabilities        
Convertible promissory notes  1,500,000   1,500,000 
Canada Emergency Business Loan Act  -   44,144 
Accrued interest, related party  1,193,896   690,772 
Loan, related party  704,000   - 
         
Total liabilities  17,676,282   12,043,351 
         
Stockholders’ Equity (Deficit)        
Preferred Series A-2, par value $0.0001, 4,200,000 shares authorized, and 3,861,197 shares issued and outstanding as of September 30, 2023, and December 31, 2022  385   385 
         
Preferred Shares A-1, par value $0.0001, 4,400,000 shares authorized and, 3,204,000 shares issued and outstanding as of September 30, 2023, and December 31, 2022  320   320 
Preferred Shares  320   320 
         
Common Stock, par value $0.0001, 30,000,000 shares authorized, and 4,550,166 shares issued and outstanding as of September 30, 2023, and December 31, 2022  455   455 
         
Additional paid in capital  22,095,370   21,206,738 
Accumulated deficit  (36,834,868)  (31,877,221)
         
Total stockholders’ equity (deficit)  (14,738,338)  (10,669,323)
         
Total liabilities and stockholders’ equity (deficit) $2,937,944  $1,374,028 

The accompanying notes are an integral part of the condensed consolidatedthese unaudited financial statements.

F-1

1

Table of ContentsONEMEDNET CORPORATION

DATA KNIGHTS ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

For the

For the

Three Months Ended

Six Months Ended

June 30, 

June 30,

    

2023

2022

2023

2022

Formation and operating costs

$

241,054

$

744,495

$

547,356

$

1,304,680

Franchise tax expense

44,400

50,000

91,881

100,000

Loss from operation costs

(285,454)

(794,495)

(639,237)

(1,404,680)

Other income (expense):

Dividends, realized and unrealized gain in Trust Account

343,002

149,350

670,401

192,403

Change in fair value of warrant liabilities

1,595,082

4,357,722

Net income (loss) before provision for income taxes

$

57,548

$

949,937

$

31,164

$

3,145,445

Provision for income taxes

(62,706)

(122,304)

Net income (loss)

$

(5,158)

$

949,937

$

(91,140)

$

3,145,445

 

 

Weighted average shares outstanding of Class A Common Stock subject to redemption

 

2,731,544

11,500,000

2,731,544

11,500,000

Basic and diluted net income (loss) per common stock

$

(0.00)

$

0.06

$

(0.01)

$

0.21

Weighted average shares outstanding of Class A and Class B non-redeemable common stock

 

4,838,792

3,460,275

4,838,792

3,460,275

Basic and diluted net income (loss) per common stock

$

(0.00)

$

0.06

$

(0.01)

$

0.21

(unaudited)

         
  

Nine Months Ended September 30,

2023
  

Year Ended December

2022
 
       
Revenue $680,918  $888,970 
Cost of Revenue  812,202   1,106,285 
Gross Profit  (131,284)  (217,315)
         
Operating Expenses        
General and administrative  2,167,719   2,034,938 
Operations  162,453   203,529 
Sales & Marketing  816,801   588,292 
Research and development  1,133,149   710,362 
Total Operating Expenses  4,280,122   3,537,121 
         
Operating loss  (4,411,406)  (3,754,436)
         
Other Expense (income)        
Interest expense  503,123   272,682 
Other expense  43,118   29,942 
 Net other expense (income)  546,241   302,624 
         
Net loss $(4,957,647) $(4,057,060)

Earnings per Share September 30, 2023 -$1.09 and 2022 -$1.44

Diluted Earnings per Share September 30, 2023 -$0.29 and 2022 -$0.44

Common Stock Equivalents September 30, 2023 12,664,133 and 2022- 8,565,053

The accompanying notes are an integral part of the condensed consolidatedthese unaudited financial statements.

F-2

2

Table of ContentsONEMEDNET CORPORATION

DATA KNIGHTS ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE AND SIXNINE MONTHS ENDED JUNESEPTEMBER 30, 2023

AND

YEAR ENDED DECEMBER 31, 2022

(UNAUDITED)

    

Class A

    

Class B

    

Additional

    

    

Total

Common Stock

Common Stock

Paid in

Accumulated

Stockholders’

    

Shares

    

Amounts

    

Shares

    

Amounts

    

Capital

    

Deficit

    

Deficit

Balance — January 1, 2023

585,275

$

59

4,253,517

$

425

$

2,242,253

$

(11,632,745)

$

(8,806,438)

Re-measurement of Class A Common Stock Subject to Possible Redemption

(583,570)

(583,570)

Net Loss

(85,983)

(85,983)

Balance — March 31, 2023 (unaudited)

585,275

$

59

4,253,517

$

425

$

2,242,253

$

(11,718,728)

$

(9,475,991)

Re-measurement of Class A Common Stock Subject to Possible Redemption

(604,656)

(604,656)

Net Loss

(5,158)

(5,158)

Balance — June 30, 2023 (unaudited)

 

585,275

$

59

4,253,517

$

425

$

1,637,597

$

(11,723,886)

$

(10,085,805)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022

                            
  Series A-2 Preferred Stock  Series A-1 Preferred Stock  Common Stock  Additional Paid-in  Accumulated  Stockholders’ 
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Deficit  Equity 
Balances, December 31, 2021  3,853,797  $385   3,204,000  $320   4,342,666  $434  $19,607,173  $(25,310,924) $    (5,702,612)
Issuance of common shares in exchange for services                  200,000   20   199,980       200,000 
Issuance of common shares in exchange for cash at $1.00 per share      -            7,500   0.75   7,499       7,500 
Stock-based compensation expense                          1,392,086       1,392,086 
                                     
2022 net loss     -       -       -        (6,566,297)  (6,566,297)
Balances, December 31, 2022  3,853,797  $385   3,204,000  $320   4,550,166  $455  $21,206,738  $(31,877,221) $(10,669,323)
Stock-based compensation expense                          504,825       504,825 
                                     
YTD Q2 2023 net loss     -       -       -        (3,267,015)  (3,267,015)
Balances, June 30, 2023  3,853,797  $385   3,204,000  $320   4,550,166  $455  $21,711,563  $(35,144,236) $(13,431,513)
Issuance of preferred shares in exchange for service at $2.50 per share                          16,000       16,000 
Stock-based compensation expense                          367,807       367,807 
YTD Q3 2023 net loss     -       -       -        (1,690,632)  (1,690,632)
Net loss     -       -       -        (1,690,632)  (1,690,632)
Balances, September 30, 2023  3,853,797  $385   3,204,000  $320   4,550,166  $455  $22,095,370  $(36,834,868) $(14,738,338)

(UNAUDITED)

    

Class A

    

Class B

    

Additional

    

    

Total

Common Stock

Common Stock

Paid in

Accumulated

Stockholders’

    

Shares

    

Amounts

    

Shares

    

Amounts

    

Capital

    

Deficit

    

Deficit

Balance — January 1, 2022

585,275

$

59

2,875,000

$

288

$

$

(8,609,810)

$

(8,609,463)

Net income

2,195,508

2,195,508

Balance — March 31, 2022 (unaudited)

585,275

$

59

2,875,000

$

288

$

$

(6,414,302)

$

(6,413,955)

Re-measurement of carrying value of Class A redeemable stock to redemption value

(1,150,000)

(1,150,000)

Net income

949,937

949,937

Balance — June 30, 2022 (unaudited)

585,275

$

59

2,875,000

$

288

$

$

(6,614,365)

$

(6,614,018)

The accompanying notes are an integral part of the condensed consolidatedthese unaudited financial statements.

F-3

3

Table of ContentsONEMEDNET CORPORATION

DATA KNIGHTS ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

For the Six Months

Ended

June 30, 

    

2023

    

2022

Cash flow from operating activities:

  

Net income (loss)

$

(91,140)

$

3,145,445

Adjustments to reconcile net income to net cash used in operating activities:

Dividends, realized and unrealized gain in Trust Account

(670,401)

(192,403)

Change in fair value of warrant liability

(4,357,722)

Changes in operating assets and liabilities:

 

Prepaid expense

83,061

Accrued expenses

 

359,473

939,956

Franchise tax payable

(61,966)

(64,008)

Income tax payable

(182,546)

Net cash used in operating activities

 

(646,580)

(445,671)

 

  

 

  

Cash flow from investing activities:

 

  

 

  

Investment of cash in Trust Account

 

(737,520)

(1,150,000)

Interest withdraw from Trust Account

458,697

Net cash used in investing activities

 

(278,823)

(1,150,000)

Cash flow from financing activities:

Advances from related parties

(300)

Proceeds from working capital loan

160,751

Proceeds from extension loans

 

737,520

1,150,000

Net cash provided by financing activities

897,972

1,150,000

 

 

Net change in cash

 

(27,432)

(445,671)

Cash at the beginning of the period

 

30,870

453,151

Cash at the end of the period

$

3,438

$

7,480

 

 

Supplemental disclosure of non-cash financing activities:

 

 

Re-measurement of Class A common stock subject to possible redemption

$

1,188,225

$

1,150,000

  Nine Months Ended September 30, 2023  Yearend December 31, 2022 
       
Cash flow from Operating Activities        
Net Loss $(4,957,647) $(4,057,060)
Adjustments to reconcile net loss to net cash flows from operating activities:        
Depreciation and amortization  19,529   16,256 
Stock-based compensation expense  888,632   52,754 
Changes in assets and liabilities:        
Accounts Receivable  (67,417)  (88,645)
Other current assets  (1,146,266)  (66,254)
Accounts payable & accrued expenses  340,525   240,822 
Deferred revenue  210,097   (306,886)
         
Net cash flows from operating activities  (4,712,547)  (4,209,013)
         
Cash used for Investing Activities        
Purchase of property and equipment  (28,801)  (48,766)
         
Cash flow from Financing Activities        
Proceeds from Canada Emergency Business Loan Act  186   (1,849)
Proceeds from Shareholders  704,000   - 
Proceeds from issuance of convertible promissory note payable  4,378,124   3,872,638 
         
Net cash flows from financing activities  5,082,310   3,870,789 
         
Net change in cash and cash equivalents  340,963   (386,990)
         
Cash and Cash Equivalents, Beginning  270,859   699,320 
         
Cash and Cash Equivalents, Ending $611,822  $312,330 

The accompanying notes are an integral part of the condensed consolidatedthese unaudited financial statements.

F-4

4

Table of ContentsONEMEDNET CORPORATION

DATA KNIGHTS ACQUISITION CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1.1 - ORGANIZATION AND DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

OneMedNet Corporation, a Delaware corporation (the “Company,” “we,” “us,” or “OneMedNet”) together with its wholly-owned subsidiary, OneMedNet Solutions Corporation, a Delaware corporation (“OneMedNet Solutions”) and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar, is an expert in clinical imaging innovation solutions that connects healthcare providers and patients and satisfies a crucial need with the life sciences. It offers direct access to clinical images and associated contextual patient record. OneMedNet proved the commercial and regulatory viability of imaging Regulatory Grade Real-World Data (“iRWDTM”), a promising emerging market, that exactly matches OneMedNet’s life science partners’ case selection protocol. All refences in this report on Form 10-Q to the “Company,” “we,” “us,” or “OneMedNet” include OneMedNet, OneMedNet Solutions and OneMedNet Technologies (Canada) Inc.

Data Knights Acquisition Corp Merger

On November 7, 2023, we consummated a merger (the “Merger”) following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp., a Delaware corporation held on October 17, 2023 (the “Company”) is a blank check company incorporated in Delaware on February 8, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of June 30, 2023, the Company had not yet commenced any operations. All activity for the period February 8, 2021 (inception) through June 30, 2023, relates to the Company’s formation and the initial public offering (the “Initial Public Offering”“Special Meeting”), and, since the closing of the initial public offering, the Company has entered into a merger agreement (as described below), and continued a search for a Business Combination candidate. The Company has selected December 31 as its fiscal year end.

The registration statement for the Company’s Initial Public Offering was declared effective on May 6, 2021. On May 11, 2021, the Company consummated the Initial Public Offering of 11,500,000 units (“Units” and, with respect to the shares of Class A Common Stock included in the Units offered, the “Public Shares”), generating gross proceeds of $115,000,000, which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 585,275 private placement units (the “Private Placement Units”) at a price of $10.00 per unit in a private placement to the Sponsor, generating gross proceeds of $5,852,750, which is described in Note 4.

Following the closing of the Initial Public Offering on May 11, 2021, an amount of $117,300,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement Units was placed in a trust account (“Trust Account”) which may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the Trust Account to the Company’s stockholders, as described below.

Transaction costs of the Initial Public Offering amounted to $6,771,112, of which $2,300,000 was for underwriting fees paid at the time of the IPO, $4,025,000 was for deferred underwriting commissions, and $446,112 was for other offering costs.

Following the closing of the Initial Public Offering $959,560 of cash was held outside of the Trust Account available for working capital purposes. As of June 30, 2023, the Company has $3,438 of cash and a working capital deficit of $2,087,360.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing of a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully affect a Business Combination.

5

Table of Contents

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Continued)

On April 25, 2022, the Company, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and a wholly-owned subsidiary of Data Knights LLC, the Company’s sponsor (the “Sponsor”), entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with OneMedNet Corporation, Inc.Acquisition Corp., a Delaware corporation (“Data Knights”), consummated a merger (the “Target”“Merger”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“OneMedNet”) pursuant to an agreement and togetherplan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“Sponsor” or “Purchaser Representative”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“Seller Representative”). Accordingly, the Merger Agreement was adopted, and the Merger and other transactions contemplated thereby (collectively, the “Business Combination”) were approved and completed.

The Business Combination was accounted for as a as a reverse recapitalization with OneMedNet as the accounting acquirer under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, the financial statements of the combined company represent a continuation of the financial statements of OneMedNet.

On June 28, 2023, the Company and Merger Sub,Data Knights entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Parties”“Purchasers”) for PIPE financing in the aggregate original principal amount of $1,595,744.70and Paul Casey, as seller representative (“Casey”). the purchase price of $1.5 million. Pursuant to the MergerSecurities Purchase Agreement, upon the closing (the “Closing”)Data Knights will issue and sell to each of the Business Combination,Purchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the Parties will effectPurchasers election at a conversion price equal to the mergerlower of Merger Sub with(i) $10.00 per share, and into the Target, with the Target continuing as the surviving entity (the “Merger”), as a result of which all(ii) 92.5% of the issued and outstanding capital stock oflowest volume weighted average trading price for the Target shall be exchanged shares often (10) Trading Days immediately preceding the Class A Common Stock of the Company upon the terms set forthConversion Date. The Purchasers’ $1.5 million investment in the Merger Agreement.

On May 5, 2022, the Company extended the date by which the Company has to consummate a business combination from May 11, 2022 to August 11, 2022 (the “First Extension”). The First Extension was the first of two three-month extensions permitted under the Company’s governing documents.

On August 10, 2022, the Company extended the date by which the Company has to consummate a business combination from August 11, 2022 to November 11, 2022 (the “Second Extension”). The Second Extension was the second of two three-month extensions permitted under the Company’s governing documents.

On October 27, 2022, the Company filed a definitive proxy statement with the SEC in connection with the Company’s solicitation of proxies for the vote by the stockholders of the Company at a special meeting of the Company’s stockholders to be held on November 11, 2022 (the “Special Meeting”).

On November 11, 2022, at 10:00 a.m. ET, the Company held a virtual special meeting of its stockholders. At the special meeting, Company stockholders entitle to vote at the special meeting cast their votesPIPE Notes closed and approved the Trust Amendment Proposal, pursuant to which the Trust Agreement was amended to extend the date on which Continental must liquidate the Trust Account established in connection with the IPO if the Company has not completed its initial business combination, from November 11, 2022 to August 11, 2023 (or such earlier date after November 11, 2022, as determined by the Data Knights Board). As a part of Special Meeting, the Company’s stockholders approved amendments to its second amended and restated certificate of incorporation (the “Extension Amendment”) and the investment management trust agreement (the “Trust Agreement”) between Continental Stock Transfer & Trust Company, as trustee (“Continental”), and the Company governing the trust account (the “Trust Account”) established in connection with the Company’s initial public offering dated May 11, 2021 (the “Trust Amendment”), which together allow the Company to extend the deadline by which it must complete its initial business combination by up to nine one-month periods. In connection with each such extension, Data Knights, LLC, the Company’s sponsor, shall cause $0.045 per outstanding share of the Company’s Class A Common Stock, or approximately $122,920, to be deposited in the Trust Account.On June 12, 2023, the Company elected to exercise its seventh of nine one-month extensionfunded contemporaneous to the Termination Date, which extended its deadline to complete its initial business combination to July 11, 2023, by depositing $0.045 per share for each Public Share outstanding after giving effect to the redemptions disclosed above, or approximately $122,920, was deposited in the Trust Account. As of June 30, 2023, the Company has executed seven one-month extensions, out of the nine, resulting in deposits of approximately $860,440 into the Trust Account.

In connection with the proposed Business Combination with the Target, the Company will provide its public stockholders with the opportunity to redeem all or a portion of their Class A Common Stock upon the completion of such Business Combination in connection with a stockholder meeting called to approve such Business Combination. In the event the proposed Business Combination with the Target is not consummated, in connection with an alternative proposed initial business combination, the Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek stockholder approval of a Business Combination at a meeting called for such purpose at which stockholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favorClosing of the Business Combination. In connection with the voting on the Extension Amendment Proposal and the Trust Amendment Proposal at the special meeting, holders of 8,768,456 shares of Class A Common Stock exercised their right to redeem those shares for cash at an approximate price of $10.42 per share, for an aggregate of approximately $91.4 million. Following the payment of the redemptions, the Trust Account had a balance of approximately $28.5 million.

6

Table of Contents

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Continued)

Based on the above, the Company will have until August 11, 2023 to consummate a Business Combination. If the Company is unable to complete a Business Combination on August 11, 2023 at the election of the Company subject to satisfaction of certain conditions, including the deposit of up $2,300,000 since the underwriters’ over-allotment option is exercised in full ($0.10 per unit), into the Trust Account, or as extended by the Company’s stockholders in accordance with the Company’s amended and restated certificate of incorporation) (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal

Effective immediately prior to the aggregate amount then on deposit inClosing, OneMedNet, Inc. issued the Trust Account, including interest earned on the funds held in the Trust Account and not previously releasedPIPE Notes to the Company to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations under Delaware law to provide for claims of creditors and the requirements of applicable law. The underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). There will be no redemption rights or liquidating distributions with respect to the Founder Shares (as defined below) or the shares of Class A Common Stock and the warrants that are included as components of the Private Placement Units. Such warrants will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.20 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the day of liquidation of the Trust Account, if less than $10.20 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claimsPurchasers under the Company’s indemnity of the underwriter of Initial Public Offering against certain liabilities, including liabilitiesprivate offering exemptions under the Securities Act of 1933, as amended (the “Securities Act”). However,

On November 8, 2023, the Company has not askedreceived from the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Sponsor’s only assets are securitiesBusiness Combination with Data Knights net cash of the Company. Therefore, the Company cannot assure its stockholders that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.$3,481.53. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Accountalso assumed $21,600 in prepaid expenses, $11,200 in amount due to claimsrelated parties, $3,556,278 in extension loan payable, $477,548 in working capital loan payable,$604,849 in warrant liabilities, common stock of creditors by endeavoring$484 and additional paid-in capital of $917,476. The working capital loan payable of $477,548 were issued to have all vendors, service providers, prospective target businesses or other entities with whichcover the Company does business, execute agreements withtransaction costs and will be paid within the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Going Concern, Liquidity and Capital Resources

As of June 30, 2023 andyear ending December 31, 2022, the Company had cash held outside of the Trust Account of $3,438 and $30,870, respectively. We intend to use the2024.

The total funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locationsBusiness Combination of prospective target businesses or their representatives or owners, review$3,481.53 was available for general corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete our initial business combination. As of June 30, 2023 and December 31,2022, the Company had working capital deficit of $2,087,360 and $1,945,267, respectively.purposes.

F-5

7

Table of Contents

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Continued)2 - GOING CONCERN

The Company’s liquidity needs prior to the consummation of its IPO were satisfied through the proceeds of $25,000 from the sale of the Founder Shares and proceed from the promissory note from sponsor of $78,925, which was repaid upon closure of the IPO. Subsequent to the IPO, the Company’s liquidity will be satisfied through a portion of the net proceeds from IPO held outside of the Trust Account.

As of June 30, 2023 and December 31, 2022, we had investments of $29,978,639 and $29,029,416 held in the Trust Account, respectively. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes paid and deferred underwriting commissions) to complete our initial business combination. We may withdraw interest to pay taxes. For the six months ended June 30, 2023, we withdraw $458,697 of interest earned on the Trust Account pay Delaware Franchise Tax and Income Tax. During the period ended December 31, 2022, we withdraw $299,601 interest earned on the Trust Account to pay Delaware Franchise Tax. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

The accompanying consolidated financial statements have beenare prepared in conformity withusing U.S. GAAP which contemplates the continuation of the Company asapplicable to a going concern, andwhich contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company does not have adequate liquidity to fund its operations through at least twelve months from the date these financial statements do not include any adjustments that might resultwere available for issuance. The Company has an accumulated deficit of $36,834,868 (2022 - $31,877,221) and has had negative cash flows from the outcome of this uncertainty. Further, we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. Management plans to address this uncertainty duringoperating activities for the period leading up to the business combination, however this cannot be guaranteed. The Company will have until August 23,ended September 30, 2023 to consummate a Business Combination. If our initial business combination is not consummated by August 23, 2023, less than oneand year after the date the financial statements are issued, then our existence will terminate, and we will distribute all amounts in the trust account. The Company intends to complete a business combination before the liquidation date and no adjustments have been made to the carrying amounts of assets or liabilities should the company be required to liquidate after such date. There can be no assurance that the Company will be able to consummate an initial business combination by August 23, 2023 and/or have sufficient working capital and borrowing capacity to meet its needs. Based upon the above analysis, management determined that theseended December 31, 2022. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

In order

To continue in existence and expand its operations, the Company will be required to, fundand management plans to, raise additional working capital deficienciesthrough an equity or finance transaction costs in connection with our initial Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officersdebt offering and directors may, but areultimately attain profitable operations. If the Company is not obligatedable to loan us funds as may be required. If we complete our initial Business Combination, we would repay such loaned amounts. In the event that our initial Business Combination does not close, we may use a portion of theraise additional working capital, held outside the Trust Accounts to repay such loaned amounts but no proceeds from our Trust Accountsit would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units identical to the Placement Units, at a price of $10.00 per unit at the option of the lender.

Risks and Uncertainties

Management is currently evaluating the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negativematerial adverse effect on the Company’s financial position, resultsoperations of the Company and continuing research and development of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statement. product.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might resultbe necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from the outcome of this uncertainty.

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into law. The IR Act provides for, among other measures, a new 1% U.S. federal excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from whom the shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased. For purposes of calculating the excise tax, however, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury Department”) has been given authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of, the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022.

8

Table of Contents

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Continued)

Any redemption or other repurchase effected by us that occurs after December 31, 2022, in connection with a Business Combination or otherwise, may be subject to this excise tax. Whether and to what extent we would be subject to the excise tax in connection with a Business Combination will depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, (ii) the nature and amount of any PIPE financing or other equity issuances in connection with the Business Combination (or any other equity issuances within the same taxable year of the Business Combination) and (iii) the content of any regulations and other guidance issued by the Treasury Department and/or the Internal Revenue Service. In addition, because the excise tax would be payable by us and not by the redeeming holder, it could cause a reduction in the value of our stock. The foregoing could cause a reduction in the cash available on hand to complete a business Combination in the required time and redeem 100% of our public shares in accordance with our amended and restated certificate of incorporation) could be subject to the excise tax, in which case the amount that would otherwise be received by our stockholders in connection with our liquidation may be reduced.

operations.

NOTE 2. 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentationPresentation and Principles of Consolidation

The accompanying consolidated financial statements are presentedhave been prepared in accordance with U.S. Dollars and conformity with accounting principles generally accepted in the United States of America (“GAAP”)GAAP and pursuant to the rules and regulations of the SEC.

Principles of Consolidation

Securities and Exchange Commission (“SEC”). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.subsidiaries.

Emerging growth company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of estimatesEstimates

The preparation of financial statements in conformity with GAAPgenerally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenuesrevenue and expenses during the reporting period.

9

Table of Contents

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual Actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all

Cash and cash equivalents consist of highly liquid, short-term investments purchased with an originala maturity of three months or less to be cash equivalents.when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC Insured limits.

Impairment of Long-Lived Assets

The Company had $3,438reviews long-lived assets, including property and $30,870equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future cash flows from the use of the asset are less than the carrying amount of that asset. There have been no losses during the quarter ended September 30, 2023 and the year ended December 31, 2022.

Cost of Revenue

Cost of Revenue is incurred by the company as a fixed cost for payroll and hosting and as a variable cost for curation and procurement of the data.

F-6

Patents and Trademarks

Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations.

Research and Development

Research and development expenditures were charged to operating expense as incurred for the periods ended September 30, 2023 and December 31, 2022.

Stock-based Compensation

The Company has a stock-based compensation plan, which is described in more detail in Note 8. The fair value of stock option and warrant grants are determined on the date of grant using the Black Scholes valuation model. Forfeitures of stock based awards are recorded as the actual forfeitures occur. Stock based compensation expense is recognized over the service period, net of estimated forfeitures, using the straight-line method.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. This guidance introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The ASU also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements. The new guidance is effective for fiscal periods beginning after December 15, 2022. Early adoption is permitted. The Company is currently assessing the effect that ASU No. 2016- 13 will have on its consolidated financial statements and related disclosures.

The Company has issued convertible promissory notes with related party investors. In order to simplify, and provide less confusion, on accounting for debt with conversion options, FASB release ASU 2020-06 in August 2020. ASU 2020-06 simplifies the accounting for convertible instruments. The embedded conversion features are no cash equivalentslonger separated from the debt with conversion features that are not required to be accounted for as derivatives under or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and therefore will be accounted for as a single equity instrument measured at its historical cost. The Company has early adopted ASU 2020-06 and therefore a derivative liability has not been recorded.

Property and Equipment

Property and equipment are summarized as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT

         
  2023  2022 
       
Computers $288,007  $259,206 
Furniture and equipment  3,785   3,785 
Total Property and Equipment  291,792   262,991 
Less: accumulated depreciation  (199,424)  (179,895)
Net Property and Equipment $92,368  $83,097 

Depreciation and amortization expense was $19,529 for the period ended September 30, 2023 and $24,807 for the year ended December 31, 2022.

Canadian Emergency Business Loan Act (CEBA)

During December 2020, the Company applied for and received a $44,330 USD CEBA loan. The loan was provided by the Government of Canada to provide capital to organizations to see them through the current challenges and better position them to return to providing services and creating employment. The loan is unsecured. The loan is interest free to December 31, 2023. If the loan is paid back by December 31, 2023, $14,776 of the loan will be forgiven. If the loan is not paid back by December 31, 2023, the full $44,330 loan will be converted to loan repayable over three years with a 5% interest rate.

The Company accounted for the loan as debt in accordance with FASB Accounting Standards Codification 470 Debt and accrued interest in accordance with the interest method under FASB ASC 835-30. Full or partial loan forgiveness with legal release reduces the liability by the amount forgiven and record a gain on extinguishment in the statement of operations.

F-7

Shareholder Loan

During the second quarter of 2023 related parties funded an additional $704,000, these loans are not tied to convertible note agreements and are non-interest bearing.

Shareholders’ Equity Series A-2 Preferred Stock

Stockholders Equity

The Series A-2 preferred stock includes a $0.15 per share annual noncumulative dividend when and if declared by the board of directors. No dividends have been declared as of September 30, 2023 and December 31, 2022. The Series A-2 preferred stock also includes a liquidation preference of 1.25 times the original issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Company and have a preference upon liquidation over Series A-1 preferred stock and common stock.

Each share of Series A-2 preferred stock may be converted into equal shares of common stock at the option of the holder at any time. In addition, the Series A-2 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the public at the then applicable conversion price in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $20 million in proceeds, net of underwriting discounts and commissions. Each share of Series A-2 preferred stock has voting rights equal to the number of shares of common stock then issuable upon conversion of such share of preferred stock.

The Company is obligated to redeem shares of Series A-2 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the holders of Series A-2 Preferred Stock and a majority of the Series A-1 Preferred Stock consent otherwise.

Series A-1 Preferred Stock

The Series A-1 preferred stock includes a $0.15 per share annual noncumulative dividend when and if declared by the board of directors. No dividends have been declared as of June 30, 2023 and December 31, 2022, respectively.

Trust Account

Upon2022. The Series A-1 preferred stock also includes a liquidation preference of 1.25 times the closingoriginal issue price plus any declared but unpaid dividends upon the liquidation, dissolution, merger or sale of substantially all the assets of the Initial Public OfferingCompany and the Private Placement, $117,300,000 ($10.00 per Unit)have a preference upon liquidation over common stock.

Each share of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was held in a trust account (“Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act 1940, as amended (the “Investment Company Act”), which willSeries A-1 preferred stock may be invested only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.

Offering Costs Associated with the Initial Public Offering

Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as offering costs allocated to warrants in the consolidated statements of operations. Offering costs associated with the Public Shares were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemableconverted into equal shares of common stock (including shares of common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, shares are classified as stockholders’ equity. The Company’s Class A Common Stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events.

On June 30, 2023, there are 585,275 shares of Class A Common Stock related to the Private Placement Units (Note 8) outstanding, which are not subject to redemption, and 2,731,544 shares of Class A Common Stock outstanding, which are subject to possible redemption.

If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. The accretion or remeasurement is treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital).

10

Table of Contents

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

As of June 30, 2023 and 2022, the Class A Common Stock reflected on the balance sheet are reconciled in the following table:

For the Six

Months Ended

June 30, 

2023

2022

Contingently redeemable Class A Common Stock – Opening Balance

$

28,750,110

$

117,300,000

Plus:

 

Re-measurement of carrying value to redemption value

 

1,188,226

1,150,000

Contingently redeemable Class A Common Stock - Ending Balance

 

29,938,336

118,450,000

Net income (loss) per share

Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock shares outstanding for the period. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the Initial Public Offering and warrants issued as components of the Private Placement Units (the “Placement Warrants”) since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

The Company applies the two-class method in calculating earnings per share. The contractual formula utilized to calculate the redemption amount approximates fair value. The Class feature to redeem at fair value means that there is effectively only one class of stock. Changes in fair value are not considered a dividend for the purposes of the numerator in the earnings per share calculation. Net income per common share is computed by dividing the pro rata net income (loss) between the redeemable shares and the non-redeemable shares by the weighted average number of common shares outstanding for each of the periods. The calculation of diluted income (loss) per common stock does not consider the effect of the warrants issued in connection with the IPO since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable for 12,085,275 shares of common stock in the aggregate.

The following table reflects the calculation of basic and diluted net income (loss) per common share:

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30, 

     

2023

2022

2023

     

2022

Redeemable Class A common shares

    

  

Numerator:

 

Net income (loss) allocable to common stock subject to possible redemption

$

(1,861)

$

730,219

$

(32,885)

$

2,417,911

Denominator: weighted average number of redeemable common share

 

2,731,544

11,500,000

2,731,544

11,500,000

Basic and diluted net income (loss) per redeemable common share

$

(0.00)

$

0.06

$

(0.01)

$

0.21

Non-redeemable Class A and Class B common shares

 

 

Numerator:

Net income (loss) allocable to common stock not subject to redemption

$

(3,297)

$

219,718

$

(58,255)

$

727,534

Denominator: weighted average number of non-redeemable common shares

4,838,792

3,460,275

4,838,792

3,460,275

Basic and diluted net income (loss) per non-redeemable common share

$

(0.00)

$

0.06

$

(0.01)

$

0.21

11

Table of Contents

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. At June 30, 2023 and 2022, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair value of financial instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except warrant liabilities (See Note 9).

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

Income Taxes

The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 and 2022, respectively. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

Our effective tax rate was 108.96% and 0% for the three months ended June 30, 2023 and 2022, respectively. Our effective tax rate was 392.45% and 0% for the six months ended June 30, 2023 and 2022, respectively. The effective tax rate differs from the statutory tax rate of 21% for the three months ended June 30, 2023 and 2022, due to transaction costs and the valuation allowance on the deferred tax assets.

12

Table of Contents

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Recently Issued Accounting Standards

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, “Debt — Debt with Conversion and Other Options” (Subtopic 470-20) and “Derivatives and Hedging — Contracts in Entity’s Own Equity” (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for the Company for the fiscal year beginning after December 15, 2023, including interim periods within those fiscal years.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

NOTE 3. INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one share of the Company’s Class A Common Stock, $0.0001 par value, and one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one share of Class A Common Stock at an exercise price of $11.50 per whole share (see Note 9).

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the Initial Public Offering, the Sponsor purchased an aggregate of 585,275 Private Placement Units at a price of $10.00 per Private Placement Unit for an aggregate purchase price of $5,852,750.

The Private Placement Units are identical to the Units, except that (a) the Private Placement Units and their component securities will not be transferable, assignable or saleable until 30 days after the consummation of the Company’s initial business combination except to permitted transferees and (b) the Placement Warrants, so long as they are held by the Sponsor or its permitted transferees, (i) may be exercised by the holders on a cashless basis and (ii) will be entitled to registration rights.

NOTE 5. RELATED PARTY TRANSACTIONS

Introducing Advisor Agreement

On June 26, 2021, the Company entered into an introducing advisor agreement (the “Introducing Advisor Agreement”) with ARC Group Limited, the Company’s financial advisor (“ARC”), pursuant to which ARC will make strategic introductions to the Company of potential target companies and/or their subsidiaries, affiliates, or representatives (each an “Advisor Target”) who may be interested in potential business combinations with the Company. In consideration for ARC’s services under the Introducing Advisor Agreement, we agreed to (i) pay to ARC (a) a retainer of $50,000 upon execution of the Introducing Advisor Agreement and (b) a success fee of $100,000 upon the closing our initial business combination, and (ii) cause to be issued to ARC equity interests in the post-combination company representing a five-percent (5%) ownership interest in the post-combination company, if at any time prior to June 25, 2022 (the “Termination Date”), or within six (6) months after the consummation of an initial business combination or any financing with any Advisor Target or any affiliate of an Advisor Target (the “Equity Issuance”).

On March 22, 2022, the Company and ARC entered into the First Amendment to the Introducing Advisor Agreement, pursuant to which both parties agreed that the Company would pay to ARC an additional success fee equivalent to five percent (5%) on any PIPE that was brought by ARC in connection with the Company’s initial business combination upon the closing of the Company’s initial business combination.

13

Table of Contents

NOTE 5. RELATED PARTY TRANSACTIONS (Continued)

On December 31, 2022, the Company and ARC entered into the Second Amendment to the Introducing Advisor Agreement, pursuant to which both parties agreed to extend the Termination Date to December 31, 2024, and to change the performance condition for the Equity Issuance from the closing of an initial business combination to the execution of a business combination agreement. On December 31, 2022, following the execution of the Second Amendment to the Introducing Advisor Agreement, the performance condition for the Equity Issuance was deemed to have been met, and ARC was issued 1,378,517 shares of the Company’s Class B Common Stock, up to 143,766 shares of which are subject to forfeiture if the public stockholders exercise redemption rights with respect to any of the remaining outstanding shares of Class A Common Stock.

Founder Shares

On February 25, 2021, the Company issued an aggregate of 2,875,000 shares of Class B Common Stock (the “Founder Shares”) to the Sponsor for an aggregate purchase price of $25,000. On February 25, 2021, the Sponsor transferred 15,000 shares to the Company’s Chief Executive Officer, 15,000 shares to the Company’s Chief Financial Officer and 5,000 shares to two of the Company’s independent directors. Following the determination of the Company’s third independent director, on March 23, 2021, the Sponsor transferred 5,000 shares to such independent director. The Founder Shares which the Sponsor and its permitted transferees will collectively own, on an as-converted basis, represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. In connection with the Introducing Advisors Agreement, on December 31, 2022, ARC was granted 1,378,517 shares of Class B common stock, $0.0001 par value per share, up to 143,766 of which are subject to forfeiture by ARC if the Company’s public shareholders exercise redemption rights with respect to any of outstanding shares of Class A common stock.

The Sponsor has agreed not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A) six months after the completion of a Business Combination or (B) the date on which the Company completes a liquidation, merger, capital stock exchange or similar transaction that results in the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property. Notwithstanding the foregoing, if the last reported sale price of the Company’s Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Business Combination, the Founder Shares will be released from the lock-up.

Promissory Note — Related Party

On February 8, 2021, the Sponsor committed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing and was payable on the earlier of July 31, 2021 or the completion of the Initial Public Offering. On June 1, 2021, the $78,925 outstanding under the promissory note was repaid in full. On June 30, 2023 and December 31, 2022, there is no amount outstanding under the promissory note.

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into units at a price of $10.00 per unit. The Units will be identical to the Private Placement Units. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. On June 30, 2023 and December 31, 2022, there is $367,832 and $207,081 outstanding under the Working Capital Loans, respectively.

14

Table of Contents

NOTE 5. RELATED PARTY TRANSACTIONS (Continued)

The Company’s second amended and restated certificate of incorporation provides that, if the Company anticipates that it may not be able to consummate a Business Combination within 12 months from the closing of the Company’s initial public offering, the Company may, by resolution of the Company’s board if requested by the Sponsor, extend the period of time to consummate a Business Combination up to two times, each by an additional three months (for a total of up to 18 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account as set out below. Pursuant to the terms of the Company’s second amended and restated certificate of incorporation and the trust agreement entered into between the Company and Continental Stock Transfer & Trust Company, in order for the time available for the Company to consummate the initial Business Combination to be extended, the Sponsor or its affiliates or designees, upon five business days advance notice prior to the applicable deadline, must deposit into the Trust Account $1,150,000 since the underwriters’ over-allotment option is exercised in full ($0.10 per unit), on or prior to the date of the applicable deadline, for each of the available three month extensions, providing a total possible Business Combination period of 18 months at a total payment value of $2,300,000 since the underwriters’ over-allotment option is exercised in full ($0.10 per unit) (the “Extension Loans”). Any such payments would be made in the form of non-interest-bearing loans. If the Company completes its initial Business Combination, the Company will, at the option of the Sponsor, repay the Extension Loans out of the proceeds of the Trust Account released to the Company or convert a portion or all of the total loan amount into unitsholder at a price of $10.00 per unit, which units will be identical to the Private Placement Units. If the Company does not complete a Business Combination, the Company will repay such loans only from funds held outside of the Trust Account. Furthermore, the letter agreement among the Company and the Company’s officers, directors, and the Sponsor contains a provision pursuant to which the Sponsor will agree to waive its right to be repaid for such loans to the extent there is insufficient funds held outside of the Trust Account in the event that the Company does not complete a Business Combination. The Sponsor and its affiliates or designees are not obligated to fund the Trust Account to extend the time for the Company to complete the initial Business Combination. The public stockholders will not be afforded an opportunity to vote on the extension of time to consummate an initial Business Combination from 12 months to 18 months described above or redeem their shares in connection with such extensions. Pursuant to the foregoing, on May 5, 2022, the Company extended the date by which the Company had to consummate a business combination from May 11, 2022 to August 11, 2022. On August 10, 2022, the Company extended the date by which the Company had to consummate a business combination from August 11, 2022 to November 11, 2022.

As described in Note 1, on November 11, 2022, the Stockholders of the Company approved the Extension Amendment and the Trust Amendment to allow the Company to extend the deadline by which it must complete its initial business combination by up to nine one-month periods from November 11, 2022. In connection with each such extension, Data Knights, LLC, the Company’s sponsor, caused $0.045 per outstanding share of the Company’s Class A Common Stock, or approximately $122,920, deposited in the Trust Account in connection with the exercise of the monthly extension. In connection with each such extension, the Company will have until August 11, 2023 to consummate a Business Combination(see Note 10). On June 30, 2023 and December 31, 2022, there is $3,283,358 and $2,545,838 outstanding under the Extension Loan, respectively.

Administrative Services Arrangement

Commencing on the date of the prospectus and until completion of the Company’s Business Combination or liquidation, the Company may reimburse ARC Group Ltd., an affiliate of the Sponsor, up to an amount of $10,000 per month for office space, secretarial and administrative support. For the three months ended June 30, 2023 and 2022, we have incurred $30,000 in fees under this agreement, respectively. For the six months ended June 30, 2023 and 2022, we have incurred $60,000 in fees under this agreement, respectively.

15

Table of Contents

NOTE 6. COMMITMENTS AND CONTINGENCIES

Registration Rights

Pursuant to a registration rights agreement entered into on May 6, 2021, the holders of the Founder Shares, Private Placement Units (including the securities contained therein), the units (including the securities contained therein) that may be issued upon conversion of the Working Capital Loans, and any shares of Class A Common Stock issuable upon the exercise of the Placement Warrants and any shares of Class A Common Stock, warrants (and underlying Class A Common Stock) that may be issued upon conversion of the units issued as part of the working capital loans and Class A Common Stock issuable upon conversion of the founder shares are entitled to registration rights. The holders of a majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities.time. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequentSeries A-1 preferred stock shares are automatically convertible into common shares upon the sale of shares of common stock to the completion ofpublic at the then applicable conversion price in a Business Combination and rights to require the Company to register for resale such securitiesfirm commitment underwritten public offering pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to becomean effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriters Agreement

The Company granted the underwriter a 45-day option to purchase up to 1,500,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. The aforementioned option was exercised on May 11, 2021.

The underwriter was paid a cash underwriting discount of two percent (2.00%) of the gross proceeds of the Initial Public Offering, or $2,300,000. In addition, the underwriter is entitled to a deferred fee of three and a half percent (3.50%) of the gross proceeds of the Initial Public Offering, or $4,025,000. The deferred fee was placed in the Trust Account and will be paid in cash upon the closing of a Business Combination, subject to the terms of the underwriting agreement.

Right of First Refusal

For a period beginning on May 7, 2021 and ending 12 months from the closing of a business combination, we have granted the underwriters a right of first refusal to act as lead-left book running manager and lead left manager for any and all future private or public equity, convertible and debt offerings during such period. In accordance with FINRA Rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of our Registration Statement.

First Amendment to the Introducing Advisor Agreement

On March 22, 2022, the Company and ARC entered into the First Amendment to the Introducing Advisor Agreement, pursuant to which both parties agreed that the Company would pay to ARC an additional success fee equivalent to five percent (5%) on any PIPE that was brought by ARC in connection with an initial business combination upon the closing of an initial business combination.

Second Amendment to the Introducing Advisor Agreement

On December 31, 2022, the Company and ARC entered into the Second Amendment to the Introducing Advisor Agreement, pursuant to which both parties agreed to extend the Termination Date to December 31, 2024, and to change the performance condition for the Equity Issuance from the closing of an initial business combination to the execution of a business combination agreement. On December 31, 2022, following the execution of the Second Amendment to the Introducing Advisor Agreement, the performance condition for the Equity Issuance was deemed to have been met, and ARC was issued 1,378,517 shares of the Company’s Class B Common Stock, up to 143,766 shares of which are subject to forfeiture if the public stockholders exercise redemption rights with respect to any of the remaining outstanding shares of Class A Common Stock.

16

Table of Contents

NOTE 7. WARRANT LIABILITY

Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable 30 days after the completion of a Business Combination and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any shares of Class A Common Stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares1933, as amended, resulting in at least $20 million in proceeds, net of Class A Common Stock issuable upon exerciseunderwriting discounts and commissions. Each share of the warrants is then effective and a current prospectus relating to those shares of Class A Common Stock is available, subjectSeries A-1 preferred stock has voting rights equal to the Company satisfying its obligations with respect to registration. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of its initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement or a new registration statement covering the shares of Class A Common Stock issuable upon exercise of the warrants, to cause such registration statement to become effective and to maintain a current prospectus relating to those shares of Class A Common Stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of Class A Common Stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the Company’s initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption.. Notwithstanding the above, if the Company’s shares of Class A Common Stock are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, it may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event it does not so elect, it will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

Redemption of warrants when the price per Class A Common Stock equals or exceeds $18.00. Once the warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the reported last sale price of the Class A Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and certain issuances of Class A Common Stock and equity-linked securities) for any 20 trading days within a 30-trading day period commencing no earlier than the date the warrants become exercisable and ending on the third business day before the date on which the Company sends the notice of redemption to the warrant holders.

If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

17

Table of Contents

NOTE 7. WARRANT LIABILITY (Continued)

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Class A Common Stockcommon stock then issuable upon exerciseconversion of such share of preferred stock.

The Company is obligated to redeem shares of Series A-1 Preferred Stock in the occurrence of a Deemed Liquidation Event unless a majority of the warrants may be adjustedholders of Series A-1 Preferred Stock consent otherwise.

Common Stock

In 2023, in certain circumstances includingconnection with services performed by the Board of Directors, common shares of 100,000 were issued at $1.00 per share. These were expensed as general and administrative expenses in the eventstatement of operations.

F-8

Stock Options

During 2020, the Company adopted a new equity incentive plan (the Plan), which provides for the granting of incentive and nonqualified stock dividend, or recapitalization, reorganization, merger or consolidation. However,options to employees, directors, and consultants. As of December 31, 2020, the warrants will notCompany has reserved 3,000,000 shares of common stock under the Plan. The Company believes that such awards better align the interests of its employees with those of its stockholders. Option awards are generally granted with an exercise price equal to the fair market value of the Company’s stock at the date of grant; those option awards generally vest with a range of one to four years of continuous service and have ten-year contractual terms. As there is no public data available for the share price valuation, the Company considers the Fair Market Value of $1 to be adjusted for issuance of Class A Common Stock at a price below itson the conservative side and similar to the exercise price. Additionally,Certain option awards provide for accelerated vesting if there is a change in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Window and the Company liquidates the funds heldcontrol, as defined in the Trust Account, holdersPlan. The Plan also permits the granting of warrants will not receive anyrestricted stock and other stock-based awards. Unexercised options are cancelled upon termination of such fundsemployment and become available under the Plan.

Information with respect to their warrants, nor will they receive any distribution from the Company’s assets held outsideoptions outstanding is summarized as follows:

SCHEDULE OF OPTIONS OUTSTANDING

  

Options

Outstanding

  

Weighted-Average

Exercise Price

  

Aggregate

Intrinsic Value

 
Outstanding as of December 31, 2022  1,031,000  $1.00  $1,031,000 
Cancelled  (168,740)        
Outstanding as of September 30, 2023  862,260  $1.00  $862,260 
             
Options exercisable as of September 30, 2023  739,424  $1.00  $739,424 

As of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. The Placement Warrants were identical to the Public Warrants underlying the Units being sold in the Proposed Public Offering, except that the Placement Warrants and the Class A Common Stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

In addition, if (x) the Company issues additional shares of Class A Common Stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A Common Stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price and the $10.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to the greater of the Market Value and the Newly Issued Price.

The Placement Warrants will be identical to the Public Warrants underlying the Units being sold in the Proposed Public Offering, except that the Placement Warrants and the Class A Common Stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

At June 30, 2022 and December 31, 2022, the Company accounted for the aggregate 12,085,275 warrants issued in connection with the Initial Public Offering (the 11,500,000 Public Warrants and the 585,275 Placement Warrants) in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value, with the change in fair value recognized in the Company’s statement of operations.

18

Table of Contents

NOTE 8. STOCKHOLDER’S EQUITY

Preferred Shares — The Company is authorized to issue 1,000,000 preferred shares with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. At JuneSeptember 30, 2023 and December 31, 2022, there were no preferred shares issued or outstanding.

Class A Common Stock 862,260— The Company is authorized to issue 100,000,000 shares of Class A Common Stock and 1,031,000 common stock options outstanding respectively, with a par valueweighted average remaining contractual life of $0.0001 per share. Holders5.32 and 7.11 years, respectively.

As of the Company’s Class A Common Stock are entitled to one vote for each share. At JuneSeptember 30, 2023 and December 31, 2022, there were 2,731,544 shares739,424 and 567,581 common stock options exercisable at a weighted average remaining contractual life of Class A Common Stock issued4.89 and outstanding that were subject5.56 years, respectively.

Black Scholes Assumptions

The determination of the fair value of stock options using an option valuation model is affected by the Company’s stock price valuation, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on volatilities of similar companies over a period of time equal to possible redemption and 585,275 sharesthe expected term of non-redeemable Class A Common Stock issued and outstanding that were issuedthe stock options. The volatilities of similar companies are used in connectionconjunction with the private placement (Note 4).Company’s historical volatility because of the lack of sufficient relevant history for the Company’s

Class B Common Stock — 

common stock equal to the expected term. The Companyexpected term of the employee stock options represents the weighted average period for which the stock options are expected to remain outstanding. The expected term assumption is authorized to issue up to 10,000,000 sharesestimated based primarily on the options’ vesting terms and remaining contractual life and employees’ expected exercise and post- vesting employment termination behavior. The risk-free rate for periods within the contractual life of Class B Common Stock with a parthe option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.

The fair value of $0.0001 per share. Holders of the Company’s Class B Common Stock are entitled to one votestock options was estimated assuming no expected dividends and the following weighted average assumptions:

SCHEDULE OF FAIR VALUE OF STOCK OPTIONS

  2022  2011 
Expected life in years  5.89   6.08 
Risk-free interest rate  0.55%  0.49%
Expected dividend yield  0.00%  0.00%
Expected volatility  32%  60%

The total expense recognized for each share. On February 25, 2021,share-based payments was $20,132 for the Sponsor transferred 15,000 shares toperiod ending September 30, 2023 and $45,584 for the Company’s Chief Executive Officer, 15,000 shares to the Company’s Chief Financial Officer and 5,000 shares to two of the Company’s independent directors. Following the determination of the Company’s third independent director, on March 23, 2021, the Sponsor transferred 5,000 shares to such independent director.

Onyear ended December 31, 2022, ARC Group Limited,2022. These costs are included in the Company’s Financial Advisor, was granted 1,378,517 sharesstatements of Class B common stock with a par valueoperations. As of $0.0001 per share, up to 143,766 of which are subject to forfeiture if the Company’s public stockholders exercise redemption rights with respect to any of the Company’s remaining outstanding shares of Class A common stock.

Accordingly, at JuneSeptember 30, 2023 there was $8,591and as of December 31, 2022, there was $75,987 of unrecognized compensation costs related to stock option grants which will be recognized over the next two years.

F-9

Stock Warrants

In 2021, there were 4,253,517174,102 outstanding common stock warrants issued for service at a weighted average exercise price of $0.10. The weighted average remaining contractual life was 3.71 years as of September 30, 2023.

In 2022 for the exercise price of $1.00, the company issued 145,746 warrants for 2021 service and 294,000 warrants for 2022 service, 2,056,000 in warrants were issued attached to convertible notes. The weighted average remaining contractual life of the warrants issued in 2022 is 3.80 years.

For the period ending September 30 2023, the company issued 1,550,000 warrants attached to convertible notes. The weighted average remaining contractual life of these warrants is 4.74 years.

All warrants vested immediately upon grant issuance. The Company expensed $852,500 for the period ended September 30, 2023 and $1,346,288 in Fiscal 2022 in relation to the issuance of the Warrants.

 SCHEDULE OF STOCK WARRANTS

  

Options

Outstanding

  

Weighted-Average

Exercise Price

  

Aggregate

Intrinsic Value

 
Outstanding as of December 31, 2022  2,669,848  $0.94  $2,513,156 
Issued  1,550,000         
Outstanding as of September 30, 2023  4,219,848  $0.96  $4,063,156 
             
Warrants exercisable as of September 30, 2023  4,219,848  $0.96  $4,063,156 

Commitments, Contingencies, and Concentrations Operating lease

The Company has a month-to-month lease for a suite at a cost of $575 per month.

The Company incurred $5,666 for the period ended September 30, 2023 and $7,694 for the year ended December 31, 2022 of rent expense.

Receivable from SPAC for IPO Related Costs

During 2022, the company entered a Business Combination Agreement with SPAC Data Knights. $2,059,975 of SPAC related expenses are on the Balance Sheet as receivable to be received at close of the merger.

NOTE 4 — ACCOUNTS RECEIVABLE, NET

Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2022 the Company established allowances of $102,700. The net receivable balances outstanding are fully collectible.

NOTE 5 PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. The straight-line method is used for computing depreciation and amortization. Assets are depreciated over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred.

F-10

NOTE 6 RELATED PARTY TRANSACTIONS

Convertible Promissory Notes held by Related Party

For the period ending September 2023, the Company entered into various Convertible Promissory Notes (“Note”) with related party investors totaling $2,100,000 (2022 - $4,700,000) and unrelated party investors of $1,775,000 (2022 - $440,000). The Notes issued are unsecured and bear an interest rate of six percent annually from the date of issuance until the outstanding principal is paid or converted. On November 11, 2022 the Convertible note agreement was amended and restated in order to (i) provide for the sale and issuance to Purchasers from the effective date of January 1, 2022 and after the date of this Agreement of up to an additional $4,000,000 aggregate principal amount of Notes and warrants to purchase shares of Class B Common Stock issuedthe Company’s capital stock, (ii) provide for the sale and outstanding.issuance to Purchasers who purchased Notes under the Prior Agreement between the Effective Date and the date of this Agreement of warrants to purchase shares of the Company’s common stock at an exercise price of $1.00 per share; (iii) extend the maturity date of all outstanding Notes from December 31, 2022 to October 31, 2023.

Holders

The principal and unpaid accrued interest on each Note will convert; (i) automatically, upon the Company’s issuance of Class A Common Stock and Class B Common Stock will vote together asequity securities (the “Next Equity Financing”) in a single class on all other matters submittedtransaction, or series of related transactions, with aggregate gross proceeds to a votethe Company of stockholders, except as required by law.

The shares of Class B Common Stock will automatically convertat least $5,000,000, into shares of Class A Commonthe Company’s capital stock issued to investors in the Next Equity Financing, at a conversion price equal to the lesser of (A) a 20% discount to the lowest price per share of shares sold in the Next Equity Financing, or (B) $2.50 per share; (ii) at the noteholder’s option, in the event of a defined Corporate Transaction while such Note remains outstanding, into shares of the Company’s Series A-2 Preferred Stock at a conversion price equal to $2.50 per share; and (iii) at the timenoteholder’s option, on or after the Maturity Date while such Note remains outstanding, into shares of the Business Combination onCompany’s Series A-2 Preferred Stock at a one-for-one basis, subjectconversion price equal to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and$2.50 per share.

If a Corporate Transaction occurs before the like. In the case that additional shares of Class A Common Stock,repayment or equity linked securities, are issued or deemed issued in excessconversion of the amounts offered inNotes, the Initial Public Offering and related toCompany will pay at the closing of the Corporate Transaction to each noteholder that elects not to convert its Notes in connection with such Corporate Transaction an amount equal to the outstanding principal amount of such noteholder’s Note plus a Business Combination,20% premium. “Corporate Transaction” means (a) a sale by the ratio at which sharesCompany of Class B Common Stock shall convertall or substantially all of its assets, (b) a merger of the Company with or into shares of Class A Common Stock will be adjusted (unlessanother entity (if after such merger the holders of a majority of the Company’s voting securities immediately prior to the transaction do not hold a majority of the voting securities of the successor entity) or (c) the transfer of more than 50% of the Company’s voting securities to a person or group.

During November 2019, the Company entered into a Convertible Promissory Note (“Note”) agreement with a related party investor. The total amount of the Note is $1,500,000. The Note is unsecured and bears interest at a rate of four percent annually from the date of issuance until the outstanding sharesprincipal is paid or converted. The Note matures on January 1, 2025. The Note shall automatically convert into the next offering of Class B Common Stock agree to waivepreferred stock upon closing of such adjustment with respect to any such issuance or deemed issuance) so that thenext equity financing. The number of shares of Class A Common Stock issuablepreferred stock to be issued upon conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed on the date of all sharesconversion, by the conversion price. The conversion price is 100 percent of Class B Common Stock will equal,the lowest price per share paid for the next equity preferred stock by other investors in the aggregate, onnext equity financing. In the event that prior to the conversion or repayment of amounts owed, the Company completes a financing transaction in which the Company sells equity securities but such transaction does not qualify as next equity financing (i.e. an as converted basis, 20%“alternative financing”), then the principal and unpaid accrued interest may (upon written election of the sumpurchaser holding the Note) convert into the securities issued by the Company in the alternative financing. The number of alternative financing equity securities to be issued upon such conversion shall be equal to the number obtained by dividing the outstanding principal and unpaid accrued interest owed by an amount equal to 100 percent multiplied by the lowest price per share at which the alternative financing equity securities are sold and issued for cash in the alternative financing.

As of September 30, 2023 $13,865,000 and as of December 31, 2022 there was $9,990,000 in outstanding principal balance on the Notes, respectively, and $1,193,896 and $690,772 in accrued interest, respectively, all included in long-term liabilities on the balance sheet. There have been no payments of principal or interest to date. In connection with the $3,875,000 in convertible notes issued in 2023 (Fiscal 2022 - $5,140,000), 1,550,000 (Fiscal 2022 - 2,056,000) in warrants were issued.

F-11

NOTE 7 REVENUE RECOGNITION

Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.

The steps the company uses to determine revenue recognition are as follows: identification of the totalcontract with a customer, identification of the performance obligations, determining the transaction price, allocation of the transaction price to the performance obligation and recognition of revenue when the Company satisfies the performance obligation.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.

The Company generates revenue from two streams: (1) iRWDTM (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients.

iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer.

Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The company invoices its Beam customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.

The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction.

The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned.

Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

NOTE 8 INCOME TAXES

Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amount and the tax basis of assets and liabilities. The Company provides for deferred taxes at the enacted tax rate that is expected to apply when the temporary differences reverse. The Company has recorded a full valuation allowance against the net deferred tax asset due to the uncertainty of realizing the related benefits.

The Company has generated both federal and state net operating losses (NOL) of approximately $21 million and $23 million, respectively, which if not used, will begin to expire in 2030. The Company believes that its ability to fully utilize the existing NOL carryforwards could be restricted on a portion of the NOL by changes in control that may have occurred or may occur in the future and by its ability to generate net income. The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impairs its NOL carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability.

F-12

Components of deferred income taxes are as follows as of December 31:

SCHEDULE OF DEFERRED INCOME TAXES

  2022  2021 
Deferred Tax Assets        
Net operating loss carry forward $6,973,587  $5,604,237 
Stock Compensation  481,144   467,925 
Other  53,268   51,617 
Gross deferred tax assets  7,507,999   6,123,778 
Less valuation allowance  (7,507,999)  (6,123,778)
Net deferred tax assets $-  $- 

The change in the valuation allowance was $1,384,220 and $764,878 for the years ended December 31, 2022 and 2021, respectively.

The effective tax rate for the years ended December 31, 2022 and 2021 differs from the federal and state statutory rates due to the full valuation allowance.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statement is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The tax years from inception through December 31, 2022 remain subject to examination by all major taxing authorities due to the net operating loss carryovers. The Company is not currently under examination by any taxing jurisdiction. The Company did not incur any interest or penalties during the years ended December 31, 2022 or 2021.

NOTE 9 — SHAREHOLDERS’ DEFICIT

The Company is authorized to issue 100,000,000 shares of common stock, outstanding upon the completionpar value of the Initial Public Offering plus all$0.0001 per share (“Common Stock”), and 1,000,000 shares of Class A Common Stock and equity linked securities issued or deemed issued in connection with aundesignated preferred stock, par value of $0.0001 per share. Before the Business Combination, (excluding anythe Company was authorized to issue 200,000,000 shares or equity linked securities issued, or to be issued, to any seller in a Business Combination, and any private placement-equivalent units and its underlying securities issued to the Sponsor or its affiliates upon conversion of loans made to the Company).

The Company may issue additional common stock, orpar value of $0.0001 per share, and 20,000,000 shares of preferred stock to complete its Business Combination or under an employee incentive plan after completionshares, par value of its Business Combination.

$0.0001 per share.

19

Table of ContentsBusiness combination with Data Knights Acquisition Corp.

NOTE 9. FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s assets and derivative warrant liabilities that are measured at fair value on a recurring basis as of June 30,

On November 7, 2023, and December 31, 2022 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value:

June 30, 2023

Quoted Prices in

Significant Other

Significant Other

Active Markets

Observable Inputs

Unobservable Inputs

Description

    

(Level 1)

    

(Level 2)

    

(Level 3)

Asset:

 

  

 

  

 

  

Investments held in Trust Account

$

29,978,639

$

$

Warrant Liabilities:

 

Public Warrants

$

345,000

$

$

Private Placement Warrants

$

$

$

17,558

December 31, 2022

    

Quoted Prices in

    

Significant Other

    

Significant Other

Active Markets

Observable Inputs

Unobservable Inputs

Description

(Level 1)

(Level 2)

(Level 3)

Asset:

Investments held in Trust Account

$

29,029,416

$

$

Warrant Liabilities:

Public Warrants

$

345,000

$

$

Private Placement Warrants

$

$

$

17,558

The Warrants are measured at fair value on a recurring basis. The Public Warrants were valued initiallyconsummated the Merger with Data Knights and at each reporting period that the warrants were not actively traded, using a Monte Carlo simulation. Asissued an aggregate of June 30, 2023 and December 31, 2022, the Public Warrants were valued using the instrument’s publicly listed trading price, which is considered to be a Level 1 measurement due to the use of an observable market quote in an active market. Private Placement Warrants were valued using a Monte Carlo valuation model using level 3 inputs at initial valuation and as of June 30, 2023 and December 31, 2022.

At June 30, 2023 and December 31, 2022, assets held in the Trust Account were invested solely in BlackRock US Treasury mutual fund of $29,978,639 and $29,029,416, respectively.

The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the consolidated statement of operations.

The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the Initial Public Offering. Accordingly, the Company classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined by the Monte Carlo simulation. This liability is subject to remeasurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification.

20

Table of Contents20,000,000

NOTE 9. FAIR VALUE MEASUREMENTS (Continued)

The Company utilized a Monte Carlo simulation to estimate the fair value of the Public warrants at each reporting period for its warrants that are not actively traded. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility shares of its common stock based on historical volatilityto the former shareholders of select peer companies that matchesOneMedNet Corporation. On June 28, 2023, the expected remaining lifeCompany and Data Knights entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Purchasers”) for PIPE financing in the aggregate original principal amount of $1,595,744.70 and the purchase price of $1.5 million. Pursuant to the Securities Purchase Agreement, Data Knights will issue and sell to each of the warrants. The risk-free interest rate is based onPurchasers, a new series of senior secured convertible notes (the “PIPE Notes”), which are convertible into shares of Common Stock at the U.S. Treasury zero-coupon yield curve on the grant date forPurchasers election at a maturity similarconversion price equal to the expected remaining lifelower of (i) $10.00 per share, and (ii) 92.5% of the warrants.lowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. The expected lifePurchasers’ $1.5 million investment in the PIPE Notes closed and funded contemporaneous to the Closing of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. On June 22, 2021, the Public Warrants surpassed the threshold waiting period to be publicly traded. Once publicly traded, the observable input qualifies the liability for treatment as a Level 1 liability. As such, as of June 30, 2023 and December 31, 2022, the Company classified the Public Warrants as Level 1.

The estimated fair value of the Private Placement Warrants is determined using Level 3 inputs. Inherent in a Monte Carlo model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s common stock that matches the expected remaining life of the Warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. For the three months ended June 30, 2023 and December 31, 2022, there were no transfers between levels.

The following table provides quantitative information regarding Level 3 fair value measurements inputs as their measurement dates:Business Combination.

    

June 30, 2023

    

December 31, 2022

(Private Warrants)

    

(Private Warrants)

Exercise price

 

$

11.50

$

11.50

Share price

$

10.89

 

$

10.44

Expected term (years)

5.11

 

5.12

Probability of Acquisition

1.9

%

2.75

%

Volatility

4.9

%

4.2

%

Risk-free rate

4.04

%

3.91

%

Dividend yield (per share)

$

0.00

$

0.00

The change in the fair value of the derivative warrant liabilities for the three months ended June 30, 2023 and 2022 is as follows:NOTE 10 SUBSEQUENT EVENTS

    

Private Warrants

    

Public Warrants

    

Total Warrant Liability

Fair value as of December 31, 2022

$

17,558

$

345,000

$

362,558

Change in valuation inputs or other assumptions(1)

 

Fair value as of June 30, 2023

$

17,558

$

345,000

$

362,558

    

Private Warrants

    

Public Warrants

    

Total Warrant Liability

Fair value as of December 31, 2021

$

251,668

$

4,600,000

$

4,851,668

Change in valuation inputs or other assumptions(1)

 

(117,640)

 

(2,645,000)

 

(2,762,640)

Fair value as of June 30, 2022

$

134,028

$

1,955,000

$

2,089,028

(1)Changes in valuation inputs or other assumptions are recognized in the change in fair value of warrant liability in the consolidated statement of operations.

21

Table of Contents

NOTE 10. SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, theThe Company has evaluated allsubsequent events or transactions that occurred afteroccurring through October 23, 2023, the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identified any subsequentavailable for issuance, for events that would have required adjustmentrequiring recording or disclosure in the Company’s financial statements other than as described below.

On July 12, 2023, the Company elected to exercise its eighth of nine one-month extension to the Termination Date, which extended its deadline to complete its initial business combination to August 11, 2023, by depositing $0.045 per share for each Public Share outstanding after giving effect to the redemptions disclosed above, or approximately $122,920, was deposited in the Trust Account.

On August 11, 2023, the Company held a “Special Meeting”. At the Special Meeting, the Company stockholders entitled to vote at the Special Meeting (the “Stockholders”) cast their votes and approved the proposal (the “Trust Amendment Proposal”) to authorize the Company to enter into Amendment No. 2 to the Trust Agreement (the “Trust Agreement Amendment”) to amend the Trust Agreement to allow the Company to extend beyond August 11, 2023 the date by which either the Company must have completed its initial business combination or Continental must liquidate the Trust Account established in connection with the IPO (the “Trust Account”). Following approval of the Trust Amendment Proposal by the Stockholders, the Company and Continental promptly entered into the Trust Agreement Amendment.  The Company is able to extend its termination date in a series of up to nine (9) one-month extensions until May 11, 2024 in exchange for depositing into Trust Account with Continental Stock Transfer and Trust Company the lesser of $75,000 or $0.045 per share for each public share outstanding (the “Extension Amount”).

In connection with the voting on the Extension Amendment Proposal and the Trust Amendment Proposal at the Special Meeting, holders of 1,018,846 shares of Class A ordinary shares exercised the right to redeem such shares for cash.

statements.

F-13

22

Item

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References to the “Company,” “us,” “our,” or “we” refer to Data Knights Acquisition Corp. The following discussion and analysis of ourthe Company’s financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included herein.

Cautionary Note Regarding Forward-Looking Statements

All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward- looking statements. When used in this Form 10-Q, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to us or the Company’s management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results may differ materially due to various factors, including, but not limited to:

our ability to complete our initial business combination with the Target (as defined below) or an alternative business combination;
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;
in the event the Business Combination (as defined below) is consummated, our ability to implement business plans, forecasts, and other expectations regarding the Target after the completion of the proposed transactions and optimize the Target’s business;
in the event the Business Combination is not consummated, the ability of our officers and directors to generate a number of potential alternative acquisition opportunities;
in the event the Business Combination is not consummated, our pool of prospective target businesses;
our public securities’ potential liquidity and trading;
the lack of a market for our securities;
our continued liquidity and our ability to continue as a going concern;
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; or
our financial performance.

All subsequent written or oral forward-looking statements attributable to us or persons acting on the Company’s behalf are qualified in their entirety by this paragraph.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with theaudited financial statements and the notes related thereto contained elsewherewhich are included in “Item 1. Financial Statements and Supplementary Data” of this Quarterly Report on Form 10-Q. Certain information contained in the discussion and analysis set forth below includes forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements that involve risksas a result of many factors, including those set forth under “Special Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q and uncertainties.“Item 1A. Risk Factors” in our Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (“Commission”) on September 30, 2023.

23

Overview

The Company is

OneMedNet Corporation, a blank check company formedDelaware corporation (the “Company,” “we,” “us,” or “OneMedNet”) together with its wholly-owned subsidiary, OneMedNet Solutions Corporation, a Delaware corporation (“OneMedNet Solutions”) and its wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the lawsprovisions of the StateBusiness Corporations Act of British Columbia whose functional currency is the Canadian dollar, is an expert in clinical imaging innovation solutions that connects healthcare providers and patients and satisfies a crucial need with the life sciences. It offers direct access to clinical images and associated contextual patient record. OneMedNet proved the commercial and regulatory viability of imaging Regulatory Grade Real-World Data (“iRWDTM”), a promising emerging market, that exactly matches OneMedNet’s life science partners’ case selection protocol. All refences in this report on Form 10-Q to the “Company,” “we,” “us,” or “OneMedNet” include OneMedNet, OneMedNet Solutions and OneMedNet Technologies (Canada) Inc.

We were originally incorporated as a Delaware corporation on February 8, 2021 under the name “Data Knights Acquisition Corp” as a special purpose acquisition company, formed for the purpose of effecting a merger, sharecapital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to effectuate its initial business combination using cash from the proceeds of itsOn May 11, 2021, we consummated an initial public offeringoffering. On November 7, 2023, we consummated a merger (the “Initial Public Offering”“Merger”) andfollowing the private placement consummated in connection therewith (the “Private Placement”),approval at the proceedsspecial meeting of the saleshareholders of the Company’s securities in connection with its initial business combination, shares issued to the owners of the target of the initial business combination, debt issued toData Knights Acquisition Corp., a bank or other lenders or the owners of the target, or a combination of the foregoing.

The issuance of additional shares in connection with an initial business combination to the owners of the target or other investors:

·

may significantly dilute the equity interest of investors, which dilution would increase if the anti-dilution provisions in the Class B Common Stock resulted in the issuance of Class A Common Stock on a greater than one -to-one basis upon conversion of the Class B Common Stock;

·

may subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common stock;

·

could cause a change in control if a substantial number of shares of our common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

·

may have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and

·

may adversely affect prevailing market prices for our Class A Common Stock and/or warrants.

Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:

·

default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;

·

acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

·

our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;

·

our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;

·

our inability to pay dividends on our common stock;

·

using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes;

·

limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;

·

increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;

·

limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and

24

·

other purposes and other disadvantages compared to our competitors who have less debt.

We expect to continue to incur significant costs in the pursuit of our initial business combination. We cannot assure you that our plans to complete our initial business combination will be successful.

Initial Business Combination

The Merger Agreement

On February 11, 2022, we,Delaware corporation held on October 17, 2023 (the “Special Meeting”), Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and a wholly-owned subsidiary of Data Knights LLC, the Company’s sponsor (the “Sponsor”), entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with OneMedNet Corporation, Inc.Acquisition Corp., a Delaware corporation (“Data Knights”), consummated a merger (the “Target”“Merger”) with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), a Delaware corporation (“OneMedNet”) pursuant to an agreement and togetherplan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, OneMedNet, Data Knights, LLC, a Delaware limited liability company (“Sponsor” or “Purchaser Representative”) in its capacity as the representative of the stockholders of Data Knights, and Paul Casey in his capacity as the representative of the stockholders of OneMedNet (“Seller Representative”). Accordingly, the Merger Agreement was adopted, and the Merger and other transactions contemplated thereby (collectively, the “Business Combination”) were approved and completed.

The Business Combination was accounted for as a as a reverse recapitalization with OneMedNet as the accounting acquirer under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, the financial statements of the combined company represent a continuation of the financial statements of OneMedNet.

On June 28, 2023, the Company and Merger Sub,Data Knights entered into a Securities Purchase Agreement (the “SPA”) with certain investors (collectively referred to herein as the “Parties”“Purchasers”) for PIPE financing in the aggregate original principal amount of $1,595,744.70 and Paul Casey, as seller representative (“Casey”).the purchase price of $1.5 million. Pursuant to the MergerSecurities Purchase Agreement, upon the closingData Knights will issue and sell to each of the transactions contemplated therebyPurchasers, a new series of senior secured convertible notes (the “Business Combination”“PIPE Notes”), we will effectwhich are convertible into shares of Common Stock at the mergerPurchasers election at a conversion price equal to the lower of Merger Sub with(i) $10.00 per share, and into the Target, with the Target continuing as the surviving entity (the “Merger”), as a result of which all(ii) 92.5% of the issuedlowest volume weighted average trading price for the ten (10) Trading Days immediately preceding the Conversion Date. The Purchasers’ $1.5 million investment in the PIPE Notes closed and outstanding capital stockfunded contemporaneous to the Closing of the Target shall be exchanged sharesBusiness Combination.

Effective immediately prior to the Closing, OneMedNet, Inc. issued the PIPE Notes to the Purchasers under the private offering exemptions under Securities Act of 1933, as amended (the “Securities Act”).

The Business Combination occurred after the Class A Common Stockperiod for which the financial information herein is presented. The financial information included in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” reflects the historical operations of the Company upon the terms set forth as follows: the Target’s stockholders collectively shall be entitled to receive from the Company, in the aggregate, a number of Company’s securities with an aggregate value equal to (a) $200,000,000 minus (b) the amount, if any, by which the Target’s net working capital amount exceeds the net working capital amount (but not less than zero), minus (c) the amount of Closing Net Indebtedness (as defined in the Merger Agreement) minus (d) the amount of any transaction expenses, provided that the merger consideration otherwise payable to the Target’s stockholders is subject to adjustment after the Closing in accordance with the terms of the Merger Agreement. The obligations of the parties to consummate the Business Combination are subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (a) the representations and warranties of the respective Parties being true and correct subject to the materiality standards contained in the Merger Agreement; (b) material compliance by the Parties of their respective pre-closing covenants and agreements, subject to the standards contained in the Merger Agreement; (c) the approval by the Company’s stockholders of the Business Combination; (d) the approval by the Target’s stockholders of the Business Combination; (e) the absence of any Material Adverse Effect (as defined in the Merger Agreement) with respect to the Company or with respect to the Target since the effective date of the Merger Agreement that is continuing and uncured; (f) the election of the members of the post-Closing Board consistent with the provisions of the Merger Agreement, a majority of which are to be independent in accordance with the Nasdaq rules; (g) the Company having at least $5,000,001 in tangible net assets upon the Closing; (h) the entry into certain ancillary agreements as of the Closing; (i) the lack of any notice or communication from, or position of, the U.S. Securities and Exchange Commission (the “SEC”) requiring the Company to amend or supplement the Prospectus and Proxy Statement (as defined below); and (j) the receipt of certain closing deliverables.

In connection with entry into the Merger Agreement, the Company entered into Voting Agreements with the Target’s stockholders pursuant to which the Target’s stockholders have agreed to vote their securities in favor of the approval of the Merger Agreement and the Business Combination, be bound by certain covenants and agreements relatedprior to the Business Combination and to take other customary actions to causethe combined operations after the Business Combination, unless otherwise noted.

4

Business Overview

OneMedNet is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data3 or iRWDTM. OneMedNet’s innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to occur. The Company, the Sponsor,clinical images and the Target also entered intoassociated contextual patient record. OneMedNet’s innovative technology proved the commercial and regulatory viability of imaging Real-World Data, an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OMN’s Life Science partners Case Selection Protocols and paves the way for Real World Evidence.

OneMedNet was founded in 2006 to solve a Sponsor Support Agreement pursuantdeficiency in how clinical images were shared between healthcare providers. This resulted in OMN’s initial product BEAMTM image exchange that enabled the successful sharing of images for more than a decade with OMN’s largest customer being the Country of Ireland.

OneMedNet continued to innovate by responding to the demand for and utilization of Real-World Data and Real-World Evidence, specifically data that focused on clinical images with its associated contextual clinical record. We were able to leverage internal technological competencies along with OneMedNet’s formidable healthcare provider installed base from its first product with BEAMTM to become the first RWD solution for Life Science companies with its launch of iRWDTM in 2019.

OneMedNet provides innovative solutions that unlock the significant value contained within clinical image archives. With a growing federated network of 95+ healthcare facilities, OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a Federated group of healthcare facilities. The term “healthcare facilities” refers specifically to the hospitals, integrated delivery networks (“IDNs”) and imaging centers that provide imaging to OneMedNet, which represent the Sponsorcore source of our data. At present, OneMedNet works with more than 95 facilities who provide regulatory grade imaging to us. OneMedNet has agreedaccess to vote its Company securitiesthese more than 95 facilities because these 95+ contracted facilities have more than 200 locations among them including offices and clinics, which in favortotal generates regulatory grade imaging from more than 200 customers. Among these customers, all are data providers and some are data purchasers.

Significant Market Opportunities

A recent report by Deloitte, “Measuring the Return from Pharmaceutical Innovation 2020,” revealed that there is a pressing need to optimize processes and fundamentally change the drug development paradigm through the use of digital and transformative approaches. The COVID-19 pandemic spurred on need for greater innovation in fact, according to Deloitte’s report, as of 2020, 70% of the approvalbiopharma interviewees noted a lack of research-grade data as hindering their efforts to incorporate Real World Evidence in their research and development (“R&D”). Moreover, 80% of the Merger Agreementbiopharma interviewees reported that they are presently entering, or seeking to enter, strategic partnerships to access new sources of Real-World Data because obtaining this data would accelerate their time to market substantially.

OneMedNet has the knowledge, tools, and experience to access and harmonize complete patient profiles across fragmented data silos. We use robust real-world datasets to offer customized consulting services to generate fit-for-purpose data and insights for their stakeholders instead of providing terabytes of data. We curate information to the most stringent multi-level stratified requirements while providing unmatched data accuracy and ensuring the security and privacy of protected health information. Moreover, we deliver this curated data quickly and efficiently to address the rapidly growing needs of life science researchers and to speed life science product development.

Numerous factors have accelerated the adoption of Real World Evidence, including an industry-wide shift from volume-to-value-based payment models, personalized medicine, and the Business Combinationneed to adapt clinical trials during the pandemic. These factors have influenced regulatory bodies globally and fuel interest in using Real World Evidence to take other customary actions“understand and demonstrate the value of pharmaceutical and medical device innovations.”

5

The global Real World Evidence solutions market size was valued at $37.2 billion in 2020 and is expected to causeexpand at a compound annual growth rate (CAGR) of 7.6% from 2021 to 2028 according to Grand View Research. The drug development and approvals segment accounted for the Business Combinationhighest revenue share of around 28.9% in 2020. Real-world evidence solutions services allow pharmaceutical companies and healthcare providers as well as payers for efficient management of operations and accelerate the process of drug development and its approval, which fuels market growth. Support from regulatory bodies for using Real World Evidence solutions and an increase in research and development spending are anticipated to occur.boost the market growth.

The Merger Agreement

With the growing need for evidence generated from Real-World Data, the increasing importance of epidemiological data in decision making, and agreements related thereto are further describeda shift from volume to value-based care, there has been an increased focus on patient registries, a rise in the Form 8-K, filed by us on April 25, 2022.

Business Combination Period

At a special meetingadoption of EMR in hospitals, and exponential growth in mobile health data and social media which have resulted in the generation of huge amounts of medical data. In 2021, the real-world datasets segment is estimated to account for the larger share of 51.2% of the Company’s stockholders heldglobal real-world evidence solutions market. The market size of this segment is projected to reach $1,792.0 million by 2028 from $1,038.3 million in 2021, at a CAGR of 8.1% during the forecast period according to Meticulous Research® Analysis.

Based on November 11, 2022,end user, the stockholdersglobal Real World Evidence solutions market is segmented into pharmaceutical, biotechnology, and medical device companies; healthcare payers; healthcare providers; and other end-users (academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies). In 2021, the pharmaceutical, biotechnology, and medical device companies segment is estimated to account for the largest share of 36.5% of the Company approvedglobal real-world evidence solutions market. The market size of this segment is projected to reach $2,025.7 million by 2028 from $739.7 million in 2021, at a CAGR of 15.5% during the First Amendmentforecast period according to Meticulous Research® Analysis. The large share of this segment is primarily attributed to the Second Amendedincreasing importance of Real World Evidence studies in drug development and Restated Certificateapprovals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

Key Factors that Affect Our Results of IncorporationOperations

Competition from our providers of Real World Data.

Our business is affected by many factors which we discuss under the Company, givingheading “Risk Factors” in our definitive Registration Statement on Form S-4 dated September 21, 2023 and filed with the CompanyCommission on October 2, 2023, and in subsequent filings. The following are a few of those key factors that may affect our financial condition and results of operations:

OneMedNet’s business is highly competitive. Competition could present an ongoing threat to the rightsuccess of OneMedNet’s business, which competition could result from national and regional providers of imaging data, which could affect our ability to extendobtain and retain new customers and pricing pressures. We cannot assure you that we will be able to build our network in a timely or cost-effective manner, efficiently acquire additional customers or achieve target projected returns by penetrating the market as effectively as projected if OneMedNet is unable to compete effectively for imaging date byproviders and RWD customers. As a result, OneMedNet’s business and operating results could be harmed.

In some instances, our competitors have easier access to financing, greater resources, greater operating capabilities and efficiencies of scale, stronger brand-name recognition, longstanding relationships with customers, and more customers. This provides these competitors with certain advantages in competing against us, including the ability to aggressively promote their products in markets in which we may compete. This competition may affect our ability to add and retain customers, which in turn adversely affects our business, financial condition and results of operations.

6

In the Company must (i) consummateRWD and real-world evidence (“RWE”) arena, there is a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination involvinghigh number of service providers globally who sell electronic health records. The competition can be organized into two groups — the Companyfirst is RWD providers that access imaging along with electronic health records. This includes firms such as Flatiron, Aetion, ConcertAI, Life Image and one or more businesses, (ii) cease its operations if it fails to completeOptum among many others. These groups have deep disease insights but do not focus on imaging, and, we believe, are not imaging experts. The other group includes firms such business combination,as Nuance and (iii) redeem or repurchase 100% of the Company’s Class A Common Stock included asTruveta that provide support for research projects using RWE where imaging may be part of the units solddeliverables but imaging is not the central focus of these companies in our opinion. We believe that anywhere imaging is required to diagnosis, assess disease progression, regression, status quo or measure the impact of a therapy, device or procedure, OneMedNet has the required radiology imaging to support these clients.

There’s a reason OneMedNet’s customer base is growing as it develops its reputation as a reliable source for regulatory-grade imaging RWD. We believe it is because it requires specialized expertise in Artificial Intelligence/Machine Learning technology, data privacy/security, as well as expertise in clinical patient condition(s) and healthcare record keeping. Having, or achieving, expertise in all essential disciplines is a challenging achievement. Our current customer base is in the Initial Public OfferingUnited States, Canada, Ireland, Israel, Germany, Netherlands, Norway and the United Kingdom. OneMedNet has plans to expand into Africa and Asia, we expect these expansions to be completed in 2023, however there is no assurance of that timetable. OneMedNet has a team of experienced curators with previous radiology, technical and clinical expertise. OneMedNet had a significant head start with our clinical image exchange solution which served to launch the company nearly a decade ago. Finally, OneMedNet has the most experienced and clinically trained data curators in the industry. This team appreciates the complexity and criticality of clinical data and can effectively communicate with both Provider and Life Science specialists.

Nevertheless, we believe that competition for users of OneMedNet’s products and services will be intense. Although OneMedNet intends to continue to develop a global platform for its OneMedNet iRWD™ solution, it will face strong competition in its business.

Results of Operations

Development of Our Technology

Since our inception, we have focused on attracting and retaining best-in-class talent to provide innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. Employing our proven OneMedNet iRWD™ solution, we securely de-identify data, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with cutting-edge proprietary technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous Real-World Data Life Science requirements.

We continue to invest in employee recruitment and retention to advance our technology. Additionally, our team has made purposeful and foundational technological investments in hardware and software. We believe these early investments in our technology will enable us to move toward additional technical innovation more safely and quickly than would otherwise be possible. When we have deemed it to be beneficial, we have entered into strategic partnerships to expand and accelerate our technology development.

We believe that our developmental approach provides us with meaningful technological advantages in areas such as our fusion of artificial intelligence and imaging with our proprietary curation and innovation approaches. The successful execution of these details of clinical imaging is what we believe will allow us to continue to differentiate ourselves through our proven OneMedNet iRWD™ solution. While we believe we are best positioned to address advanced imaging solutions, potential competition may exist from November 11,other imaging providers using other approaches. Future success will be dependent on our ability to continue to execute innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers.

7

Commercialization and Strategic Partnerships

OneMedNet set forth on a corporate journey to create safer and more intelligent care solutions for patients, providers and hospitals. The company has been solely focused on creating innovative solutions that enable healthcare providers to gain increased value from medical imaging data. Whether requesting or transferring an image, the process must be straightforward and streamlined on both ends. OneMedNet’s BEAM™ Image Sharing solution has been exceeding customer expectations for more than a decade with customer renewal rates exceeding 96%.

However, as important as the initial (or secondary) read may be to patient care, the value and impact of imaging goes well beyond an individual image. It’s about the entire patient population archive utility and the potential data mining benefits for improving care. Research institutions often have difficulty gathering cohort data — even from their own internal center(s). It’s not only cumbersome but very time consuming. And community hospitals increasingly leverage data for self-analysis and patient care advancement. Using our OneMedNet iRWD™, we can de-identify, index, and curate an archive resulting in fast, yet detailed search capabilities.

Providers can also advance healthcare on a much broader basis by sharing de-identified imaging data with external researchers. OneMedNet continually receives patient cohort requests from “Data Users” (e.g., Pharma, CRO’s, Core Labs, AI, Medical Devices). If a cohort match is found at one of our networked providers, OneMedNet will present that provider with a potential monetizing agreement. If agreement is reached, only then will the de-identified data be shared externally.

Production and Operations

OneMedNet expects to incur significant operating costs that will impact its future profitability, including research and development expenses as it continues to introduce new offerings and upgrades its existing iRWD™ offering plus additional operating costs and expenses as it scales its operations; interest expense from debt financing activities; and selling and distribution expenses as it builds its brand and markets its iRWD™.

Revenues

For the period January 1, 2022 up to nine (9) one-month extensionsSeptember 30, 202, the company generated revenue totaling $888,970 and for the period January 1, 2023 to August 11, 2023. In connection with approvalSeptember 30, 2023 the company generated revenue totaling $680,918. The decrease is attributable to an iRWD revenue delivery being delayed to of the First Amendment to the Second Amended and Restated Certificatefourth quarter of Incorporation2023.

Cost of the Company, the Sponsor caused $0.045 per outstanding share of Class A Common Stock, giving effect to redemptions made in connection with the special meeting, or approximately $122,920, to be deposited in the Trust Account in connection with the exercise of the first monthly extension of the Extended Date to December 11, 2022. Eight subsequent monthly extensions have since been exercised.Revenues

25

On August 11,In 2023, the Company held a "Special Meeting". Atchanged its accounting policy to allocate the Special Meeting, the Company stockholders entitleddiscovery portion of curation expenses to vote at the Special Meeting (the "Stockholders") cast their votesResearch and approved the proposal (the "Trust Amendment Proposal") to authorize the Company to enter into Amendment No. 2 to the Trust Agreement (the "Trust Agreement Amendment") to amend the Trust Agreement to allow the Company to extend beyond August 11, 2023 the date by which either the Company must have completed its initial business combination or Continental must liquidate the Trust Account established in connection with the IPO (the "Trust Account"). Following approval of the Trust Amendment Proposal by the Stockholders, the Company and Continental promptly entered into the Trust Agreement Amendment. The Company is able to extend its termination dateDevelopment resulting in a seriesdecrease to compensation costs of up$294,083.

Research and development expenses

Research and development expenditures were charged to nine (9) one-month extensions until May 11, 2024 in exchange for depositing into Trust Account with Continental Stock Transfer and Trust Company the lesser of $75,000 or $0.045 per share for each public share outstanding (the "Extension Amount").

In connection with the voting on the Extension Amendment Proposal and the Trust Amendment Proposal at the Special Meeting, holders of 1,018,846 shares of Class A ordinary shares exercised the right to redeem such shares for cash.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception through June 30, 2023 were organizational activities, those necessary to prepare for our Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for an initial Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Accounts. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended June 30, 2023, we had a net loss of $5,158, which consists of realized and unrealized gain and dividends of $343,002, offset with operating expense of $241,054 and franchise tax expense of $44,400 and income tax provision of $62,706.

Foras incurred for the three monthsperiods ended June 30, 2022, we had a net income of $949,937, which consists of unrealized gain from marketable securities held in the Trust Account of $149,350, change in fair value of warrant liabilities of $1,595,082 and offset by operating costs of $794,495.

For the six months ended June 30, 2023, we had a net loss of $91,140, which consists of realized and unrealized gain and dividends of $670,401, offset with operating expense of $547,356 and franchise tax expense of $91,881 and income tax provision of $122,304.

For the six months ended June 30, 2022, we had a net income of $3,145,445, which consists of unrealized gain from marketable securities held in the Trust Account of $192,403, change in fair value of warrant liabilities of $4,357,722 and offset by operating costs of $1,404,680.

Going Concern, Liquidity and Capital Resources

As of JuneSeptember 30, 2023 and December 31, 2022. OneMedNet expects to incur significant operating costs that will impact its future profitability, including research and development expenses as it continues to introduce new offerings and upgrades its existing iRWD™ offering plus additional operating costs and expenses as it scales its operations; interest expense from debt financing activities; and selling and distribution expenses as it builds its brand and markets its iRWD™. Our research and development expenses primarily consist of employee salaries and welfare, and outsourcing expenses.

Research and development costs consist of payroll, hardware and electrical engineering prototyping, cloud computing, data labeling, and third-party development services, as well as costs associated curating and testing. These costs are included within research and development within the statement of operations. We expect our research and development expenses to increase in absolute dollars as we increase our investment in scaling our proprietary technologies.

Research and development increased by $422,787 or 37.3% in the nine-months ended September 30, 2023 of $1,133,149 compared to $710,362 at yearend December 31, 2022 with the addition of employees and the change in accounting policy to allocate the discovery portion of curation expenses to research and development. In 2023, the company started allocating hosting costs specific to research and development work.

8

Other Income (Expenses), Net

Our other income (expenses) primarily includes interest expense on financings and financial related expenses.

Total other income (expense), net, increased by $243,617 or 44.6% from $302,624 of other income (expense) for the for the period ended September 30, 2022 to $546,241 of other income (expense) for the nine months ended September 30, 2023.

As a result of the foregoing, we reported a net loss of $4,057,060 for the nine months ending September 30, 2022 representing a $900,587 or 18.2% increase to a net loss of $4,957,647 for the nine months ended September 30, 2023. All net income is attributable to OneMedNet Solutions Corporation (formerly, OneMedNet Corporation).

Liquidity and Capital Resources

As of September 30, 2023, we had $611,822 in cash and cash equivalents as compared to $270,859 as of $3,438 and $30,870 outsideDecember 31, 2022. We also had $86,392 in accounts receivable as of the Trust Account, respectively. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete our initial business combination.

For the six months ended JuneSeptember 30, 2023 as compared to $18,975 as of December 31, 2022. Our accounts receivable primarily include balances due from compensation for services provided to our customers. As of September 30, 2023, our accumulated deficit was $36,834,868 as compared to $31,877,221 as of December 31, 2022 and has had negative cash used inflows from operating activities was $646,580.

Forfor the six monthsperiod ended June 30, 2022, cash used in operating activities was $445,671.

As of JuneSeptember 30, 2023 and year ended December 31, 2022, we had investments of $29,978,639 and $29,029,416 held in the Trust Accounts, respectively. We intend to use substantially all of the funds held in the Trust Accounts, including any amounts representing interest earned on the Trust Accounts (less taxes paid and deferred underwriting commissions) to complete our initial business combination. We may withdraw interest to pay taxes. During the six months ended June 30, 2023 and 2022, For the six months ended June 30, 2023, we withdraw $458,697 and nil of interest earned on the Trust Account pay Delaware Franchise Tax and Income Tax, respectively.  To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our initial business combination, the

26

remaining proceeds held in the Trust Accounts will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates the continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Further, we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. Management plans to address this uncertainty during the period leading up to the business combination; however, this cannot be guaranteed. The Company will have until August 11, 2023, subject to nine one-month extensions, to consummate a business combination. If our initial business combination is not consummated by August 11, 2023, less than one year after the date the financial statements are issued, then our existence will terminate, and we will distribute all amounts in the trust account. The Company intends to complete a business combination before the liquidation date, and no adjustments have been made to the carrying amounts of assets or liabilities should the company be required to liquidate after such date. There can be no assurance that the Company will be able to consummate an initial business combination by August 11, 2023 and/or have sufficient working capital and borrowing capacity to meet its needs. Based upon the above analysis, management determined that these2022. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In assessing our liquidity, management monitors and analyzes our cash, our ability to raise funds and to generate sufficient revenue in the future, and our operating and capital expenditure commitments. We are looking for other sources, such as raising additional capital by issuing shares of stock, to meet our needs for cash.

Cash Flows for the Nine Months Ended September 30, 2023 and 2022

The following table sets forth summary of our cash flows for the periods indicated:

  

January 1 to

September 30, 2023

  

January 1 to

September 30, 2022

 
       
Cash flow from Operating Activities        
Net Loss $(4,957,647) $(4,057,060)
Adjustments to reconcile net loss to net cash flows from operating activities:        
Depreciation and amortization  19,529   16,256 
Stock-based compensation expense  888,632   52,754 
Changes in assets and liabilities:        
Accounts Receivable  (67,417)  (88,645)
Other current assets  (1,146,266)  (66,254)
Accounts payable & accrued expenses  340,525   240,822 
Deferred revenue  210,097   (306,886)
         
Net cash flows from operating activities  (4,712,547)  (4,209,013)
         
Cash used for Investing Activities        
Purchase of property and equipment  (28,801)  (48,766)
         
Cash flow from Financing Activities        
Proceeds from Canada Emergency Business Loan Act  186   (1,849)
Proceeds from Shareholders  704,000   - 
Proceeds from issuance of convertible promissory note payable  4,378,124   3,872,638 
         
Net cash flows from financing activities  5,082,310   3,870,789 
         
Net change in cash and cash equivalents  340,963   (386,990)
         
Cash and Cash Equivalents, Beginning  270,859   699,320 
         
Cash and Cash Equivalents, Ending $611,822  $312,330 

9

Operating Activities

Net cash used in operating activities was $4,712,547 for the nine months ended September 30, 2023, primarily consisting of the following:

● Net loss of $4,957,647 for the nine months ended September 30, 2023.

● Share-based compensation of $888,632.

● Stock-based compensation expenses of $19,529.

● Accounts Receivable of $(67,417).

● Other current assets of $(1,146,266).

● Accounts payable & accrued expenses of $340,525.

● Deferred revenue of $210,097.

Financing Activities

Net cash provided by financing activities amounted to $5,082,310, for the nine months ended September 30, 2023 and primarily consisted of proceeds from the issuance of convertible promissory note payable loans of $4,378,124, Proceeds from shareholders of $704,000, and Proceeds from Canada Emergency Business Loan Act of $186.

Contractual obligations

Long Term Debt

The Company’s long-term debts included loans borrowed from banks and other financial institutions. As of September 30, 2023, future minimum loan payments are as follows:

Year ending December 31,  

Loan

Payment

 
2023  252,000  
2024  248,000  
2025    
2026    
Thereafter    
Total  500,000  
Less interest    
Balance as of September 30, 2023 $500,000  

10

Off-Balance Sheet Financing Arrangements

We did not have no obligations, assets or liabilities, which would be consideredany off-balance sheet arrangements as of JuneSeptember 30, 20232023.

Critical Accounting Policies and December 31, 2022. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual ObligationsEstimates

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay an affiliate of the Sponsor a monthly fee up to $10,000 for office space, utilities and secretarial and administrative support services. We began incurring these fees on May 7, 2021 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and our liquidation. For the six months ended June 30, 2023 and 2022, we have incurred $60,000 in fees under this agreement, respectively.

The underwriters are entitled to a deferred fee of $4,025,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Accounts solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Related Party Transactions

Working Capital Loan

In order to fund working capital deficiencies or finance transaction costs in connection with our initial business combination, our Sponsor or an affiliateOur discussion and analysis of our Sponsor or certainfinancial condition and results of operations are based upon our officers and directors may, but are not obligated to, loan us funds as may be required (the “Working Capital Loans”). If we complete our initial business combination, we would repay such loaned amounts. In the event that our initial business combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units identical to the Placement Units, at a price of $10.00 per unit at the option of the lender. As of June 30, 2023 and December 31, 2022, we had $367,832 and $207,081 in Working Capital Loans outstanding, respectively.

Extension Loan

As discussed above, on November 11, 2022, we held a special meeting of stockholders to seek stockholder approval of certain proposals to extend the date by which we must consummate a business combination from November 11, 2022 to August 11, 2023 subject to nine one-month extensions (each an “Extension”), each of which Extensions requiring us to cause to be deposited into the Trust Account an amount equal $0.045 per unit sold in the Initial Public Offering (each such deposit an “Extension Payment”).

27

In connection with the Extensions, the Sponsor agreed to loan us of the funds to make the associated Extension Payments (the “Extension Loans”). As of June 30, 2023 and December 31, 2022, we had $3,283,358 and $2,545,838 in Extension Loans outstanding, respectively.

Introducing Advisor Agreement

On June 26, 2021, we entered into an introducing advisor agreement (the “Introducing Advisor Agreement”) with ARC Group Limited, the Company’sconsolidated financial advisor (“ARC”), pursuant to which ARC will make strategic introductions to the Company of potential target companies and/or their subsidiaries, affiliates, or representatives (each an “Advisor Target”) who may be interested in potential business combinations with the Company. In consideration for ARC’s services under the Introducing Advisor Agreement, we agreed to (i) pay to ARC (a) a retainer of $50,000 upon execution of the Introducing Advisor Agreement and (b) a success fee of $100,000 upon closing our initial business combination, and (ii) cause to be issued to ARC equity interests in the post-combination company representing a five-percent (5%) ownership interest in the post-combination company, if at any time prior to June 25, 2022 (the “Termination Date”), or within six (6) months thereafter, we closed on an initial business combination or any financing with any Advisor Target or any affiliate of an Advisor Target (the “Equity Issuance”).

On March 22, 2022, we and ARC entered into the First Amendment to the Introducing Advisor Agreement, pursuant to which both parties agreed that we would pay to ARC an additional success fee equivalent to five percent (5%) on any PIPE that was brought by ARC in connection with our initial business combination upon the closing of our initial business combination.

On December 31, 2022, we and ARC entered into the Second Amendment to the Introducing Advisor Agreement, pursuant to which both parties agreed to extend the Termination Date to December 31, 2024, and to change the performance condition for the Equity Issuance from the closing of our initial business combination to the execution of a business combination agreement. On December 31, 2022, following the execution of the Second Amendment to the Introducing Advisor Agreement, the performance condition for the Equity Issuance was deemed to have been met, and ARC was issued 1,378,517 shares of the Company’s Class B Common Stock, up to 143,766 shares of which are subject to forfeiture if our public stockholders exercise redemption rights with respect to any of our remaining outstanding shares of Class A Common Stock.

Critical Accounting Policies

The preparation ofstatements. These financial statements and related disclosuresare prepared in conformityaccordance with U.S. GAAP, which requires the Company’s managementus to make estimates and assumptions that affect the reported amounts of our assets and liabilities disclosure ofand revenue and expenses, to disclose contingent assets and liabilities aton the date of the consolidated financial statements, and incometo disclose the reported amounts of revenue and expenses incurred during the periods reported. Actualfinancial reporting period. The most significant estimates and assumptions include the valuation of accounts receivable, advances to suppliers, useful lives of property and equipment, the recoverability of long-lived assets, provision necessary for contingent liabilities, and revenue recognition. We continue to evaluate these estimates and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could materially differ from those estimates. The Company has identified the following as itsSome of our accounting policies require higher degrees of judgment than others in their application.

We believe critical accounting policies:policies as disclosed in this prospectus reflect the more significant judgments and estimates used in preparation of our consolidated financial statements.

The following critical accounting policies rely upon assumptions and estimates and were used in the preparation of our consolidated financial statements:

Use of Estimates

The preparation of condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenuesrevenue and expenses during the reporting periods.

Makingperiod. Actual results could differ from those estimates. These estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimateare based on information available as of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, whichstatements. Significant estimates required to be made by management considered in formulating its estimate, could change ininclude, but are not limited to, the near term due to one or more future confirming events. Accordingly,allowance for doubtful accounts, useful lives of property and equipment, the actualimpairment of long- lived assets, valuation allowance of deferred tax assets, and revenue recognition. Actual results could differ significantly from those estimates.

Financial Instruments

Accounts Receivable

Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines fair valuethe need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. As of December 31, 2022 the Company established allowances of $102,700. The net receivable balances outstanding are fully collectible.

Revenue Recognition

Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied.

11

The steps the company uses to determine revenue recognition are as follows: identification of the contract with a customer, identification of the performance obligations, determining the transaction price, allocation of the transaction price to the performance obligation and recognition of revenue when the Company satisfies the performance obligation.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement.

The Company generates revenue from two streams: (1) iRWD (imaging Real World Data) which provides regulatory grade imaging and clinical data in the Pharmaceutical, Device Manufacturing, CRO’s and AI markets and (2) BEAM which is a Medical Imaging Exchange platform between Hospital/Healthcare Systems, Imaging Centers, Physicians and Patients.

iRWD is sold on a fixed fee basis based on assumptions that market participants would use in pricing an asset or liabilitythe number of data units and the cost per data unit committed to in the principalcustomer contract. Revenue is recognized when the data is delivered to the customer.

Beam revenue is subscription-based revenue which is recognized ratably over the subscription period committed to by the customer. The company invoices its Beam customers quarterly or most advantageous market. When considering market participant assumptionsannually in fair value measurements,advance with the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one ofcustomer contracts automatically renewing unless the following levels:customer issues a cancellation notice.

Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets.

28

Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in marketsThe Company excludes from revenue taxes collected from a customer that are not activeassessed by a governmental authority and model derived valuations whose inputsimposed on and concurrent with a specific revenue-producing transaction.

The transaction price for the products is the invoiced amount. Advanced billings from contracts are observable or whose significant value driversdeferred and recognized as revenue when earned.

Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are observable.

Level 3 Inputs: Significant inputs intogenerally recognized as revenue over the valuation model are unobservable.

contractual period. The Company does not have any recurring Level 2 or Level 3 assets or liabilities. The carrying valuereceives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of the Company’s financial instruments including its cash and accrued liabilities approximate their fair values principally because of their short-term nature.

Net Income (Loss) Per Share of Common Stock

Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock shares outstanding for the period. The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the Initial Public Offering and warrants issued as components of the Private Placement Units (the “Placement Warrants”) since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

The Company applies the two-class method in calculating earnings per share. The contractual formula utilized to calculate the redemption amount approximates fair value. The Class feature to redeem at fair value means that there is effectively only one class of stock. Changes in fair value are not considered a dividend of the purposes of the numerator in the earnings per share calculation. Net income per common share is computed by dividing the pro rata net loss between the redeemable shares and the non-redeemable shares by the weighted average number of common shares outstanding for each of the periods. The calculation of diluted income per common stock does not consider the effect of the warrants issued in connection with the IPO since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable for 11,500,000 shares of common stock in the aggregate.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

Warrant Liabilities

The Company accounts for its warrants in accordance with the guidance contained in ASC 815-40 under which the warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations. The warrants for periods where no observable traded price was available are valued using a binomial/lattice model. For periods subsequent to the detachment of the public warrants from the public units, the public warrant quoted market price will be used as the fair value as of each relevant date.

Class A Common stock subject to possible redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of June 30 2023, there were 3,316,819 shares of Class A Common Stock outstanding, excluding 2,731,544 shares of Class A Common Stock are subject to possible redemption.

29

Recent Accounting Pronouncements

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

days.

ItemITEM 3. Quantitative and Qualitative Disclosures About Market RiskQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of June 30, 2023, we were not subject to any market or interest rate risk. Following the consummation of our Initial Public Offering, the net proceeds received into the Trust Account, have been invested in U.S. government treasury bills, notes or bonds with a maturity of 185 days or less or in certain money market funds that invest solely in US treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

Not applicable.

ItemITEM 4. ControlsCONTROLS AND PROCEDURES

Disclosure controls and Proceduresprocedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officerprincipal executive officer and Chief Financial Officer,principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended JuneSeptember 30, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon thaton this evaluation, our chiefprincipal executive officer and chiefprincipal financial and accounting officer have concluded that during the period covered by this report, our disclosure controls and procedures were not effective.

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed(as defined in our reports filedRules 13a-15(e) and 15d-15(e) under the Exchange Act, such as this report, is recorded, processed, summarized, and reported withinAct) were effective at the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Our management evaluated, with the participation of our Chief Executive Officer and Principal Financial Officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of June 30, 2023, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of June 30, 2023, our disclosure controls and procedures were not effective, due to the previously disclosed material weakness in our internal control over financial reporting relating to the accounting treatment for complex financial instruments and the failure to properly account for and disclose such instruments, in addition to a material weakness in internal control related to the lack of review controls over financial reporting and related disclosures.

Management’s Report on Internal Controls over Financial Reporting

As required by SEC rules and regulations implementing Section 404 of the Sarbanes-Oxley Act, our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:level.

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our company,

30

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our consolidated financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of our internal control over financial reporting as of June 30, 2023. In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013). Based on our assessments and those criteria, management determined that we did not maintain effective internal control over financial reporting as of June 30, 2023, due to the material weakness in our internal control over financial reporting relating to the Company’s accounting for complex financial instruments and related disclosure in addition to a material weakness in internal control related to the lack of review controls over financial reporting and related disclsoures.

Management has implemented remediation steps to improve our internal control over financial reporting. Specifically, we expanded and improved our review process for complex securities and related accounting standards. We plan to further improve this process by enhancing access to accounting literature, identification and consideration of third-party professionals with whom to consult regarding complex accounting applications and implementing additional layers of reviews in the financial close process.

Changes in Internal Control over Financial Reporting

There waswere no changechanges in our internal control over financial reporting that occurred during the fiscal quarter ended JuneSeptember 30, 2023 covered by this Quarterly Report on Form 10-Q that hashave materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting, withreporting.

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the exceptionobjectives of the below.

Management notedcontrol system are met. In addition, the design of a lack of review controls overcontrol system must reflect the financial accounting close and reporting processfact that resulted in adjustments to accruals and financial statement disclosures.

The Chief Executive Officer and Chief Financial Officer performed additional accounting and financial analyses and other post-closing procedures including consulting with subject matter experts related to the accounting for temporary and permanent equitythere are resource constraints, and the restatementbenefits of controls must be considered relative to their costs. Because of the Prior Financials. The Company’sinherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management has expended, and will continue to expend, a substantial amount of effort and resources for the remediationoverride of the material weaknesscontrol. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and improvementthere can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of our internalthese inherent limitations in a cost-effective control over financial reporting. The Company’s management will review the financial statement close processsystem, misstatements due to error or fraud may occur and perform a more thorough review of the closing process, financial statements, filing and related workbooks and schedules. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we have expanded and will continue to improve these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards.not be detected.

12

31

PART II - II—OTHER INFORMATION

ItemITEM 1. Legal ProceedingsLEGAL PROCEEDINGS

None.

From time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief. The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position, results of operations or cash flows.

ItemITEM 1A. Risk FactorsRISK FACTORS

As of the date of this Quarterly Report on Form 10-Q, there

There have been no material changes to thein our risk factors from those disclosed in Part I, Item 1A. of our final prospectus dated May 6, 2021 filed with the SEC, the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and the Company’s registration statement on Form S-4/A filed on April 11, 2023, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

2022.

ItemITEM 2. Unregistered Sale of Equity Securities and Use of Proceeds.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a)Unregistered Sales of Equity Securities

None.

(b)Use of Proceeds from the Public Offering

The securities sold in our initial public offering were registered under the Securities Act on a registration statement on Form S-1 (No. 333-254029). The SEC declared the registration statement effective on May 6, 2021. There have been no material changes in the planned use of proceeds from our initial public offering as described in our final prospectus dated May 6, 2021 filed with the SEC and other periodic reports previously filed with the SEC.

(c)Purchase of Equity Securities by the Issuer and Affiliated Purchasers

None.

None.

ItemITEM 3. Defaults Upon Senior SecuritiesDEFAULTS UPON SENIOR SECURITIES

None.

Not applicable.

ItemITEM 4. Mine Safety DisclosuresMINE SAFETY DISCLOSURES

Not Applicable

Not applicable.

ItemITEM 5. Other InformationOTHER INFORMATION

None.

32Not applicable.

ItemITEM 6. ExhibitsEXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

No.

Description of Exhibit

Exhibits

3.1

2.1 †

Agreement and Plan of Merger, dated April 25, 2022, by and among Data Knights, Merger Sub, Sponsor, OneMedNet, and Paul Casey (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).

Second3.1Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on November 13, 2023).
3.2Amended and Restated Bylaws of OneMedNet Corporation (incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K, filed with the SEC on November 13, 2023)..
4.1Warrant Agreement, dated May 6, 2021, by and between Continental Stock Transfer & Trust Company and the Company (incorporated by reference to Exhibit 4.3 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).

3.2

4.2

First Amendment to the Second Amended and RestatedSpecimen Unit Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 14, 2022)

3.3

Bylaws (incorporated by reference to Exhibit 3.24.1 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).

31.1*

4.3

Specimen Class A Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).

4.4Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Company’s Form S-1/A, filed with the SEC on April 7, 2021).
10.1+Form of OneMedNet Corporation 2022 Equity Incentive Plan (incorporated by reference to Annex D to the proxy statement/prospectus which is part of the Registration Statement on Form S-4 declared effective by the SEC on September 22, 2023).
10.2Form of Registration Rights Agreement by certain OneMedNet equity holders (included as Exhibit G to Annex B to the proxy statement/prospectus).
10.3Lockup Agreement by certain OneMedNet equity holders (included as Exhibit C to Annex B to the proxy statement/prospectus).
10.4Sponsor Lock-up Agreement (as incorporated by reference to Exhibit B of Exhibit 2.1 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).
10.5Letter Agreement, dated May 6, 2021, by and between Data Knights, the initial security holders and the officers and directors of the Data Knights (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K, filed with the SEC on May 11, 2021)
10.6Voting Agreement incorporated by reference to Form 8-K filed April 25, 2022 which is included as Appendix A to Exhibit 2.2.
10.7Sponsor Support Agreement Voting Agreement. (incorporated by reference to Exhibit B to Annex B to the proxy statement/prospectus filed by Data Knights Acquisition Corp.).
10.8+Employment Agreement between OneMedNet Corporation and Aaron Green, President (incorporated by reference to Exhibit 10.8 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).
10.9+Employment Agreement between OneMedNet Corporation and Lisa Embree, Chief Financial Officer (incorporated by reference to Exhibit 10.9 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).
10.10+Employment Agreement between OneMedNet Corporation and Paul Casey, Chief Executive Officer (incorporated by reference to Exhibit 1010 to the Company’s Form 8-K, filed with the SEC on April 25, 2022).
10.11Securities Purchase Agreement dated June 28, 2023 with OneMedNet Corporation.
31.1*Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*

Inline XBRL Instance Document

101.CAL*

Inline XBRL Taxonomy Extension Calculation LinkbaseInstance Document

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*

104

Cover Page Interactive Data File (Embedded within the Inline(formatted as inline XBRL document and includedcontained in Exhibit)

Exhibit 101)

*Filed or furnished herewith.
+Management contract or compensatory plan or arrangement.

13

*    Filed herewith.

**  Furnished.

SIGNATURES

33

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DATA KNIGHTS ACQUISITION CORP.ONEMEDNET CORPORATION

Date: August 14,November 20, 2023

By:

/s/ Barry AndersonPaul Casey

Name:

Barry Anderson

Paul Casey

Title:

Chief Executive Officer

(Principal Executive Officer)

Date:August 14, 2023

/s/ Firdauz Edmin Bin Mokhtar

Name:

Firdauz Edmin Bin Mokhtar

Title:

Chief Financial Officer

(Principal Financial and Accounting Officer)

14

34